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Obstructive sleep apnea (OSA) is a potentially serious sleep disorder in 
which breathing repeatedly stops and starts during sleep. It results from an 
upper airway collapse during sleep that occurs because of an inadequate mo-
tor tone of the tongue and/or airway dilator muscles and is associated with 
intermittent hypoxia and transient arousals. Collapsibility can also be in-
creased by underlying anatomic alterations. Obesity and particularly central 
adiposity, both potent risk factors for sleep apnea, can increase pharyngeal 
collapsibility through mechanical effects on pharyngeal soft tissues [1].  
Symptoms include snoring, witnessed apneas and daytime sleepiness. OSA 
has well-established neurocognitive and cardiovascular sequelae [2]. If left 
untreated, it leads to excessive daytime sleepiness, cognitive dysfunction, 
impaired work performance and decrements in health-related quality of life 
[3]. The condition is associated with increased risk of traffic accidents, dia-
betes, hypertension, coronary artery disease and stroke.  
The apnea-hypopnea index (AHI) is commonly used to categorize the severi-
ty of OSA and it represents the average number of apneas and/or hypopneas 
per hour of recorded sleep.  
The standard first-line OSA treatment involves continuous positive air-way 
pressure (CPAP) devices, which deliver compressed air into the air-way to 
keep it open. [4]. Treatment effectiveness is limited by variable adherence to 
prescribed therapy. When only CPAP therapy is considered, a certain por-
tion of the sleep apnea population remains inadequately treated.  
Description of Technology 
A number of factors contribute to OSA pathogenesis, including decreased 
tone during sleep in the upper airway dilator muscles, especially the gen-
ioglossus [5]. This notion has led to investigations of direct electrical stimu-
lation of the motor nerve innervating the genioglossus muscle, the hypoglos-
sal nerve (HGN) [6-8]. The technology utilises an implantable device that 
electrically stimulates the hypoglossal nerve, leading to the contraction of 
the genioglossus muscle, the major muscle responsible for tongue protru-
sion. Theoretically, increasing the activity in the pharyngeal dilator muscles 
could be effective for patients who have a dysfunction in these muscles. 
 
Methods 
Answering the research questions regarding efficacy and safety-related out-
comes was based on a systematic literature search from different databases. 
The study selection, data extraction and assessing the methodological quali-
ty of the studies was performed by two review authors (ISF, AK) inde-
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Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a re-
commendation: apnea-hypopnea index (the number of apnea or hypopnea 
events per hour), level of daytime sleepiness (Epworth Sleepiness Scale) and 
quality of life (Functional Outcomes of Sleep Questionnaire). 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: serious adverse device effects (SADE), adverse events (AE) 




We included randomised controlled trials for assessing efficacy and safety, 
in addition, prospective case-series with at least 10 patients and follow-up of 
6 months for assessing safety. 
In total, 2 RCTs with 67 participants and 7 single-arm studies with 224 pa-
tients met our inclusion criteria. Neither one of the RCTs reported on safety 
outcomes. The mean age of patients was 53-57 years in the RCTs, 50-55 
years in the case series and the majority were males. 
Clinical effectiveness 
In responders to UAS treatment, selected from an uncontrolled single arm 
study, the withdrawal of therapy (control group) for 1 week resulted in sta-
tistically significant impairment of severity (AHI) of OSA, daytime sleepi-
ness (ESS) and quality of life (FOSQ), which was considered clinically rele-
vant compared to the intervention group (maintenance of therapy). After 6 
months when therapy resumed, AHI, ESS and FOSQ showed no difference 
between groups. 
Another RCT randomised patients eligible for stimulation therapy with de-
layed therapy activation. After 6 months, AHI and ESS showed no statisti-
cally significant difference between the “device active” and the control 
group. Both groups showed a considerable reduction in AHI. 
Safety 
Serious device related adverse effects (SADE) occurred in 2% of patients 
and device explantation was performed in 2% of the patients at 40 months. 
Studies with smaller sample sizes showed higher rates of SADE and device 
explantation at 6 and 12 months. 
The most recent and largest study reported 469 adverse events (AE) in 126 
participants at 40 months, but the rate of both procedure and device related 
adverse events are reported to decrease over time after implantation. 
Upcoming evidence 
Currently, there is one registered ongoing randomised controlled trial with 
an open-label, parallel assignment design for a four-month period with the 
Aura6000™ System (ImThera Medical Inc.). 
Wirksamkeit: 





2 RCTs mit 67 T. 
7 Ein-Arm-Studien  
mit 224 T. 





RCT 2: Randomisierung 
HNS vs. Sham 
keine signifikanten 
Unterschiede nach 6 Mo 
längste Studie 40 Mo 
SADE in 2 % 
469 AE in 126 P. 
1 RCT registriert 
(Aura6000™) 
1 RCT erwähnt 
(Inspire®) 
Summary 
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Another randomised controlled trial with delayed therapy activation and 6-
month follow-up is ongoing. Patient enrolment will be completed by 2016. 
The Inspire® UAS System (Inspire Medical, Inc.) will be implanted. 
Discussion 
Overall, the strength of evidence for efficacy and safety is low to very low. 
This is mainly due to one RCT with a withdrawal study design and the study 
design of single-arm studies.  
Both included RCTs are flawed due to small sample sizes and the inherent 
lack of blinding of hypoglossal nerve stimulation therapy. There is a high 
risk of bias in the withdrawal RCT associated with highly selected partici-
pants, not representative of the population affected by OSA.  
As far as information was available, the other RCT used different inclusion 
criteria. The trial has been terminated after six months. The efficacy-related 
outcomes failed to show a significant between-group difference in the reduc-
tion of sleep apnea severity, owing to major unanticipated improvements in 
the control group. Both groups showed a considerable reduction in AHI, but 
the underlying cause of improvement of AHI in the control group is un-
known.  
Although the strength of evidence for safety is very low, hypoglossal nerve 
stimulation for treatment of OSA does not seem to be related to lethal con-
sequences but only to a high number of non-serious adverse events and less 
frequent serious adverse events. 
In highly selected responders, the effects of withdrawal and resuming the 
therapy were attributable to hypoglossal nerve stimulation. However, the 
study design and the selection of responders do not allow assessing the rela-
tive effectiveness of the intervention. As responders do not represent the tar-
get population in this report, the study results cannot be used as evidence to 
derive a recommendation.  
Furthermore, it is known that a subset of eligible patients will respond to 
stimulation therapy anyway, but characteristics of responders and the extent 
to which the hypoglossal nerve stimulation is effective remain unknown. 
And, important information about the non-responders is lacking.  
The effect of stimulation therapy shown in responders was not reproducible 
in another study population eligible for stimulation therapy. The underlying 
cause of improvement of the severity of OSA independent of active stimula-
tion remains unclear. 
Long-term data regarding treatment effects, complications and compliance 
are lacking and none of the relevant clinical endpoints like cardiovascular 
morbidity or mortality were reported. Information on device durability 
beyond 40 months is lacking.  
 
Conclusion 
The current evidence is not sufficient to prove that hypoglossal nerve stimu-
lation for treating moderate-to-severe obstructive sleep apnea is more effec-
tive and equally safe compared to no treatment. New study results will po-
tentially influence the effect estimate considerably. The implantation of 
UAS seems to be relatively safe and serious adverse events relatively rare. 
 
2 RCTs 
1 RCT mit withdrawal 
design/ Randomisierung 
v. Therapierespondern: 
1-wöchiger Entzug führt 
zu Verschlechterung der 
Symptome 
 






Therapieentzugs nur  
in Therapierespondern 
gezeigt, sehr kurzer 
Zeitraum 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Die obstruktive Schlafapnoe (OSA) ist eine schlafbezogene Atmungsstörung, 
bei der es während des Schlafes wiederholt zu einem Kollaps der Rachen-
muskulatur kommt. Dadurch werden die oberen Atemwege teilweise oder 
komplett blockiert, es kommt zu Atempausen, intermittierender Hypoxämie 
und in Folge zu einer Weckreaktion des Körpers (Arousal). Begleitet werden 
die Atempausen häufig von lautem und unregelmäßigem Schnarchen. Zu 
den anatomischen Risikofaktoren gehören Adipositas mit einem BMI größer 
als 30, ein kurzer oder retrahierter Unterkiefer und laterale parapharyngeale 
Fettpolster. Der Verschluss der oberen Atemwege ist allerdings ein komple-
xer Vorgang, der von vielen Faktoren abhängig ist wie Alter, Gewicht und 
Geschlecht, Lebensstil, anatomische Besonderheiten im Rachenraum, gene-
tische Ursachen, aber auch Veränderungen im Schlaf-Wach-Rhythmus. 
Die Symptome können übermäßige Tagesmüdigkeit, beobachtete Atemaus-
setzer, Leistungsabfall im Beruf und Alltag sowie depressive Symptome um-
fassen. Neben den damit verbundenen Risiken wie erhöhter Unfallgefahr im 
Straßenverkehr, birgt die obstruktive Schlafapnoe weitere erhebliche Risi-
ken. Sie wird sehr häufig von einer arteriellen Hypertonie begleitet, das 
Herzinfarkt-, und Schlaganfall-Risiko steigt und es besteht eine erhöhte 
kardiovaskuläre Mortalität. 
Der Apnoe-Hypopnoe-Index (AHI) bezeichnet die durchschnittliche Anzahl 
von Apnoe- und Hypopnoe-Episoden pro Stunde Schlaf. Er ist ein Hinweis 
auf die Schwere einer schlafbezogenen Atmungsstörung. Es gibt allerdings 
keine einheitliche Einteilung des Schweregrads unter Verwendung des AHI. 
Laut der Amerikanischen Gesellschaft für Schlafmedizin (AASM) sowie 
nach der Medizinischen Leitlinie „Nicht erholsamer Schlaf – Schlafstörun-
gen“ liegt ein leichtgradiges OSA bei einem AHI von 5-15 vor, ab einem AHI 
>15 und <30 wird die OSA als mittelgradig, und ab einem AHI >30 als 
schwer eingestuft [9, 10].  
Etwa 2 bis 4 % der Erwachsenen leiden unter einem obstruktiven Schlafap-
noe Syndrom (OSAS), das charakterisiert ist durch einen AHI ≥5 sowie Ta-
gesschläfrigkeit. Die Prävalenz der symptomatischen OSA wird bei einem 
AHI größer als 15 mit 9 % bei Männern und 4 % bei Frauen angegeben. 
Die CPAP-Beatmung (kontinuierlicher positiver Atemwegsdruck) ist die 
gängige Schlafapnoe-Therapie bei einer mittel-bis-schwergradigen obstruk-
tiven Schlafapnoe. CPAP wird über eine Nasenmaske (Schlafapnoe-Maske) 
appliziert und stabilisiert durch einen leichten Überdruck über den gesam-
ten Atemzyklus die oberen Luftwege – vom Naseneingang bis zur Luftröhre.  
International wird die Compliance mit der CPAP Therapie mit 40-60 % an-
gegeben. Dabei nutzen 29-83 % der OSA PatientInnen die Therapie regel-
mäßig weniger als 4 Stunden [9]. Daher bleibt ein Teil der Schlaf-Apnoe Pa-
tientInnen unzureichend behandelt, wenn man nur die Therapie mit CPAP 
betrachtet. Neben anderen Behandlungsmethoden wie Unterkieferprotrusi-
onsschiene, Gewichtsreduktion, Änderung der Schlafposition mit Vermei-
dung der Rückenlage, durch ein Lagetraining oder über Hilfsmittel wie 
Schlafwesten, kann in seltenen ausgewählten Fällen auch eine Operation an 
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Das kurzfristige Therapieziel bei einer OSA besteht in der Reduktion von 
hypoxischen Episoden und Schlaffragmentierung sowie einer Reduktion 
bzw. Normalisierung des AHI, das längerfristige Ziel ist die Reduktion des 
mit OSA einhergehenden erhöhten Risikos für Herz-Kreislauf-
Erkrankungen und der erhöhten Sterblichkeitsrate. 
Beschreibung der Technologie 
Eine Mehrzahl von Faktoren sind an der Pathogenese der OSA beteiligt, ne-
ben Übergewicht als wesentlicher Kofaktor ist ein herabgesetzter Tonus der 
Muskulatur, die für das Offenhalten der oberen Atemwege im Schlaf ver-
antwortlich ist, entscheidend. Ein neuer, funktioneller Therapieansatz bei 
OSA besteht in der elektrischen Stimulation des Nervus hypoglossus wäh-
rend des Schlafes, da dieser den wesentlichen Atemwegsöffner, den Muscu-
lus genioglossus innerviert. Auf diesem Weg soll die insuffiziente Tonisie-
rung der am Offenhalten der Atemwege beteiligten Muskulatur während des 
Schlafes durch ein implantierbares System wiederhergestellt werden [6-8]. 
Die direkte Muskelstimulation des M. genioglossus durch intramuskuläre 
oder transkutane Elektroden hat sich als nicht erfolgreich herausgestellt, da 
diese Stimulation zu Schlafunterbrechungen geführt hat [11-13].  
Es wurden drei Systeme zur Stimulation des Nervus hypoglossus unter-
schiedlicher Hersteller in klinischen Studien überprüft, die alle ein CE-
Zertifikat haben. 
 Inspire® Upper Airway Stimulation (UAS) System  
(Inspire Medical Systems, Inc.) 
 Aura6000™ System (ImThera Medical, Inc.) 
Das dritte Produkt ist allerdings nicht mehr verfügbar 
 HNS/HGNS® System (Apnex Medical, Inc.) 
Allen drei Systemen gemeinsam ist die einseitige subkutane Implantation 
einer Nervenstimulatoreinheit und die direkte Stimulation des N. hypoglos-
sus durch eine anliegende Stimulationselektrode. Zwei dieser Systeme sti-
mulieren den Nervus hypoglossus atmungssynchron. Die Differenzierung 
zwischen Inspiration und Exspiration wird durch einen interkostal liegen-
den Drucksensor bei Inspire® UAS (Inspire Medical Inc.) bzw. durch einen 
subkutan liegenden Impedanzsensor bei HNS/HGNS® (Apnex Medical, 
Inc.) erreicht. Bei dem dritten System (Aura6000TM ImThera Medical Inc.) 
erfolgt die Stimulation nicht in Abhängigkeit zur Atmung, sondern kontinu-
ierlich, indem alternierend unterschiedliche Faserbündel des Nerven stimu-
liert werden und andere nicht, dadurch kommt es zu einer sich ständig ver-
ändernden aber nie verschwindenden Tonisierung der Zunge.  
Alle Systeme sind für PatientInnen mit OSA gedacht, die eine CPAP-Thera-
pie nicht vertragen bzw. damit nicht erfolgreich zu behandeln sind. Einen 
Monat nach Implantation werden sie erstmals aktiviert, grob orientierend 
im Wachzustand eingestellt und im Schlaflabor schließlich feineingestellt. 
In den USA hat das Inspire® Upper Airway Stimulation (UAS) System eine 
Zulassung der FDA für eine Untergruppe von PatientInnen mit einer mit-
tel-bis-schwergradigen obstruktiven Schlafapnoe mit AHI zwischen 20 und 
65 und ohne anatomische Auffälligkeiten, die als Ursache der OSA in Frage 
kommen. 
Therapieziel: 
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Das HNS/HGNS® System (Apnex Medical, Inc.) hat keine FDA Zulassung 
und das Aura6000™ System (ImThera Medical, Inc.) hat eine Forschungs-
ausnahmegenehmigung der FDA für eine laufende Studie (NCT02263859). 
Ein weiteres Produkt ist ein Implantat in klinischer Prüfung und weder in 
Europa noch in den USA erhältlich und hat eine Forschungsausnahmege-
nehmigung der FDA für die klinische Studie NCT02312479. 
 Nyxoah SAT System (Nyxoah) 
Nyxoah ist ein sehr kleines und minimalinvasives Gerät zur Neurostimula-
tion. Es wird mittels eines kleinen Einschnitts nahe den Nerven des Zun-
genmuskels implantiert.  
Der Bericht behandelt die Frage, ob die Behandlung von mittel-bis-schwer-
gradiger obstruktiver Schlafapnoe mittels elektrischer Stimulation des Ner-
vus hypoglossus wirksamer und zumindest genauso sicher wie „keine Inter-
vention“ ist.  
Keine Intervention meint in diesem Zusammenhang, dass das Stimulations-
system implantiert, aber nicht aktiviert wird. Ein Vergleich mit CPAP The-
rapie ist deshalb nicht möglich, weil nur PatientInnen, die keine CPAP The-
rapie tolerieren oder akzeptieren für eine Therapie mittels Stimulation des 
Nervus hypoglossus in Frage kommen. Die Aktivierung des Stimulations-
systems erfolgt in einer Schlafnacht im Schlaflabor (Titrationsnacht). Die 
Stimulation wird vom/von der Patienten/in vor dem Schlafengehen und 
nach dem Aufwachen mittels einer Fernbedienung aktiviert bzw. deakti-
viert. Daher war weder eine Verblindung des behandelten Arztes noch der 
PatientInnen in den Studien möglich. Um diesem potentiellen Informati-
onsbias entgegenzuwirken, könnte eine subtherapeutische Stimulation als 
„Scheinbehandlung“ in Erwägung gezogen werden [14]. 
 
Methoden 
Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Si-
cherheit erfolgte anhand einer systematischen Literatursuche in folgenden 
Datenbanken: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA) 
Zusätzlich wurde noch eine Handsuche durchgeführt und es gab eine An-
frage nach Studien bei den einzelnen Herstellern. Die Studienauswahl er-
folgte unabhängig durch beide Autoren (ISF, AK). Der Erstautor (ISF) 
extrahierte die Studiendaten und die Zweitautorin (AK) kontrollierte die 
Daten. 
Die Daten der für die Entscheidung herangezogenen Endpunkte wurden aus 
den einzelnen Studien zusammengefasst und nach GRADE (Grading of Re-
commendations Assessment, Development and Evaluation) bewertet. 
Zusätzlich wurde das Bias-Risiko der Studien durch die Erstautorin (ISF) 
bewertet und die Daten von der Zweitautorin (AK) kontrolliert. 
  
HNS wirksamer und 
zumindest gleich sicher 
als keine Intervention? 
Vergleich  
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Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit der Stimulation des Nervus hypoglossus 
wurden die folgenden entscheidenden Endpunkte für eine Empfehlung her-
angezogen:  
 Schweregrad der obstruktiven Schlafapnoe (AHI) 
 Tagesschläfrigkeit (Epworth Sleepiness Scale) 
 Lebensqualität (Functional Outcomes of Sleep Questionnaire) 
Kardiovaskuläre Morbidität und Mortalität sind wichtige klinische End-
punkte, wurden aber aufgrund der frühen Entwicklungsphase der Stimula-
tion des Nervus hypoglossus nicht in diesem Bericht berücksichtigt. 
Sicherheit 
Zur Bewertung der Sicherheit der Stimulation des Nervus hypoglossus wur-
den die folgenden entscheidenden Endpunkte für eine Empfehlung heran-
gezogen: 
 schwere unerwünschte produktbezogene Ereignisse (SADE) 
 unerwünschte Ereignisse (AE) 




Es wurden randomisierte kontrollierte Studien (RCTs) zur Bewertung der 
Wirksamkeit und Sicherheit eingeschlossen, die eine Behandlung einer mit-
tel-bis-schwergradigen obstruktiven Schlafapnoe mittels Stimulation des 
Nervus hypoglossus mit „keiner Intervention“ verglichen. Zusätzlich wur-
den unkontrollierte Beobachtungsstudien (sogenannte Ein-Arm-Studien) 
mit 10 oder mehr PatientInnen zur Bewertung der Sicherheit eingeschlos-
sen. 
2 RCTs mit 67 StudienteilnehmerInnen und 7 Ein-Arm-Studien mit 224 
StudienteilnehmerInnen entsprachen den Einschlusskriterien. Beide RCTs 
berichteten keine Ergebnisse zur Sicherheit. 
Das Durchschnittsalter der PatientInnen lag zwischen 53 und 57 Jahren in 
den RCTs und zwischen 50 und 55 in den unkontrollierten Beobachtungs-
studien mit einem ganz überwiegenden Anteil von Männern. Die Nachbe-
trachtungszeit der meisten Studien lag bei 6 und 12 Monaten, wobei es auch 
eine Studie mit 40 Monaten (entspricht 3 Jahren und 4 Monaten) Nachbe-
trachtungszeit gab. Die Studien untersuchten die Behandlung von mittel- 
bis schwergradiger obstruktiver Schlafapnoe, wobei sich die Einschlusskrite-
rien hinsichtlich des Schweregrads gemessen anhand des AHI sowie des Bo-
dy-Maß-Index (BMI) geringfügig unterschieden. Einer der beiden RCTs ex-
kludierte PatientInnen mit einem vollständigen konzentrischen retropalata-
len Kollaps in einer vorangegangenen medikamentös induzierten Schlafen-
doskopie. 
In einem der beiden RCTs wurde das Inspire® Upper Airway Stimulation 
(UAS) System, in dem anderen RCT das HNS/HGNS® System implantiert.  
Wirksamkeit: 





2 RCTS mit 67 T. 
7 Ein-Arm-Studien  
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Klinische Wirksamkeit 
Therapieresponder, die nach 12 Monaten Beobachtungszeit in einer unkon-
trollierten Beobachtungsstudie konsekutiv ausgewählt wurden, wurden ei-
ner 7-tägigen randomisierten kontrollierten Therapieentzugsphase unterzo-
gen. Das Ansprechen auf die Therapie wurde vorab definiert als Reduktion 
des AHI um 50 % des Ausgangswertes und AHI kleiner als 20. In der Thera-
pieentzugsgruppe (Kontrollgruppe) kam es zu einem signifikanten Anstieg 
des AHI und zu einer signifikanten Verschlechterung der Tagesschläfrigkeit 
(ESS) und der Lebensqualität (FOSQ), die auch klinisch relevant waren. In 
der Therapieerhaltungsgruppe (Interventionsgruppe) gab es keine Ände-
rung der Werte. Nach 1 Woche wurde die Therapie in der Therapieentzugs-
gruppe wieder fortgesetzt und nach 6 Monaten zeigten sich keine Unter-
schiede zwischen beiden Gruppen bei den Endpunkten AHI, ESS und 
FOSQ. 
Der zweite RCT randomisierte PatientInnen in eine Kontrollgruppe mit Im-
plantation ohne Aktivierung des Neurostimulators und eine Interventions-
gruppe mit Aktivierung. Das Ansprechen auf die Therapie wurde vorab de-
finiert als Reduktion des AHI um 50 % des Ausgangswertes und AHI klei-
ner als 20. Nach 6 Monaten zeigte sich kein statistisch signifikanter Unter-
schied des AHI und der Tagesschläfrigkeit (ESS) zwischen beiden Gruppen.  
Sicherheit 
Schwere unerwünschte produktbezogene Ereignisse (SADE) traten in 2 % 
der PatientInnen auf, eine Explantation erfolgte ebenfalls in 2 % in einem 
Beobachtungszeitraum von 40 Monaten. Studien mit kleinen Fallzahlen 
zeigten höhere Raten an schweren unerwünschten produktbezogenen Ereig-
nissen und Explantationen in einem Beobachtungszeitraum von 6 bzw. 12 
Monaten.  
Unerwünschte Ereignisse (AE) wie Schmerzhaftigkeit, vorübergehende 
Schwäche der Zunge, Unbehagen aufgrund der elektrischen Stimulation wa-
ren häufig, 469 Ereignisse traten in 126 PatientInnen in einem Beobach-
tungszeitraum von 40 Monaten auf.  
Laufende Studien 
Aktuell ist eine laufende randomisierte kontrollierte Studie registriert 
(NCT02263859). Die kontrollierte Studie läuft 4 Monate, danach wird der 
Neurostimulator auch in der Kontrollgruppe aktiviert. Die zweite Phase der 
Studie läuft weitere 8 Monate. In der Studie wird das Aura6000™ System 
(ImThera Medical Inc.) implantiert. Erste Fertigstellung ist Mai 2016. 
Eine weitere randomisierte kontrollierte Studie mit einer verzögerten Akti-
vierung der Stimulationstherapie wird in den Unterlagen des Dossiers eines 
Herstellers erwähnt. Der Beobachtungszeitraum ist 6 Monate, die laufende 
Rekrutierung von 40 PatientInnen wird im Jahr 2016 abgeschlossen sein. 
Die Studie wurde nicht in den aufgesuchten Registern und Datenbanken für 
klinische Studien gefunden.
1
 In der Studie wird das Inspire® UAS System 
(Inspire Medical Systems, Inc.) implantiert. 
                                                             
1
 ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials (EUdraCT) 
RCT 1: Randomisierung 
von Therapierespondern 




Anstieg des AHI  
und Verschlechterung 
der ESS,  
FOSQ nach Absetzen 
RCT2: Randomisierung 
HNS vs. Sham 
keine signifikanten 
Unterschiede nach 6 Mo 
längste Studie 40 Mo 
SADE in 2 % 
469 AE in 126 P. 
1 RCT registriert 
(Aura6000™) 
1 RCT erwähnt 
(Inspire®) 
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Diskussion 
Ziel des Berichts war es die Wirksamkeit und Sicherheit der Stimulation des 
Nervus hypoglossus bei der Behandlung der mittel-bis-schwergradigen obs-
truktiven Schlafapnoe im Vergleich zu keiner Intervention zu untersuchen. 
Zwei RCTs wurden für die Bewertung der Wirksamkeit herangezogen. Sie-
ben unkontrollierte Beobachtungsstudien wurden für die Bewertung der Si-
cherheit herangezogen, da keine der beiden RCTs Ergebnisse zur Sicherheit 
berichteten.  
Insgesamt inkludierten beide RCTs [14, 15] 67 PatientInnen mit mittel-bis-
schwergradiger obstruktiver Schlafapnoe, allerdings unterschieden sich die 
Inklusionskriterien, soweit diese Information für den RCT, der nur als Abs-
tract publiziert wurde, verfügbar war. In beiden Studien wurde das Anspre-
chen auf die Therapie vorab definiert, als Reduktion des AHI um 50 % des 
Ausgangswertes und AHI kleiner als 20.  
Ein RCT hatte ein „withdrawal design“ [14]. Nach 12 Monaten Beobach-
tungszeit in einer prospektiven unkontrollierten Beobachtungsstudie [16] 
wurden die ersten 46 konsekutiven PatientInnen, die ein Ansprechen auf die 
Stimulationstherapie (Therapieresponder) zeigten, entweder in die Thera-
pieentzugsgruppe (Kontrollgruppe) oder in die Therapieerhaltungsgruppe 
(Interventionsgruppe) randomisiert. Die Therapieentzugsphase dauerte 1 
Woche, danach wurde in beiden Gruppen die Stimulationstherapie für wei-
ter 6 Monate fortgesetzt.  
Die für die unkontrollierte Studie vorab definierten Ein-und Ausschlusskri-
terien erlaubten keinen Einschluss von PatientInnen mit einem vollständi-
gen konzentrischen retropalatalen Kollaps, der in einer medikamentös in-
duzierten Schlafendoskopie ausgeschlossen wurde. Daher trifft dieses Aus-
schlusskriterium auch für die selektierte randomisierte Subgruppe der un-
kontrollierten Studie zu. Es ist aber unklar, ob ein solches Ausschlusskrite-
rium auch in dem zweiten RCT zur Anwendung gekommen ist, da nur auf 
Angaben des publizierten Abstracts mit Studienergebnissen von 21 Patien-
tInnen und der Datenbank des klinischen Studienregisters
2
 zurückgegriffen 
werden konnte.  
Der zweite RCT [15] wurde vorzeitig nach einer negativen Interimsanalyse 
nach 6 Monaten beendet. Sowohl PatientInnen der Interventionsgruppe als 
auch der Kontrollgruppe wurde das HNS/HGNS® System (Apnex Medical, 
Inc.) implantiert. In der Interventionsgruppe wurde ein Monat nach der 
Implantation die Stimulation aktiviert, in der Kontrollgruppe hätte die Akt-
vierung 7 Monate nach der Implantation stattfinden sollen. Im Rahmen der 
Interimsanalyse nach 6 Monaten zeigten sich keine statistisch signifikanten 
Gruppenunterschiede betreffend Schweregrad gemessen anhand des AHI 
und der Tagesschläfrigkeit anhand des ESS aufgrund nicht erwarteter Ver-
besserungen in der Kontrollgruppe. Beide Gruppen hatten eine deutliche 
Reduktion des AHI, aber die zugrundeliegende Ursache der Verbesserung in 
der Kontrollgruppe bleibt unklar. 
Der einwöchige Therapieentzug in der RCT Subgruppe [14] führte zu einer 
Verschlechterung aller Ergebnisse betreffend die Wirksamkeit. Nach Wie-
deraufnahme der Therapie fanden sich nach 6 Monaten keine Gruppenun-
terschiede.  





1 RCT mit withdrawal 
design/ Randomisierung 
v. Therapierespondern: 
1-wöchiger Entzug führt 
zu Verschlechterung der 
Symptome 
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Kritikpunkte der beiden Studien sind vor allem die kleinen Fallzahlen und 
die der Intervention inhärente Unmöglichkeit der Verblindung von Patien-
tInnen und behandelten ÄrztInnen. Es besteht ein hohes Bias-Risiko in dem 
RCT, da aus einer unkontrollierten Beobachtungsstudie eine Subgruppe von 
Therapierespondern ausgewählt wurde, die nicht repräsentativ sind für die 
Population mit einer mittel-bis schwergradigen OSA. Weiters erlaubt eine 7 
tägige Therapieentzugsphase keine Beurteilung einer Effektivität über einen 
längeren Zeitraum.  
Die in der Studie gezeigten Effekte des Therapieentzugs und der Wiederauf-
nahme der Therapie in einer hochselektierten PatientInnengruppe, nämlich 
nachgewiesenen Therapierespondern, sind auf die Intervention zurückzu-
führen. Das Studiendesign und die Selektion von Therapierespondern er-
laubt damit allerdings keine Beurteilung der relativen Effektivität. Da The-
rapieresponder nicht die Zielgruppe des Berichts sind, können diese Stu-
dienergebnisse nicht als Evidenz für eine Empfehlung herangezogen wer-
den. 
Weiters ist bekannt, dass bestimmte PatientInnen auf die Stimulationsthe-
rapie ansprechen, aber es bleibt unklar, wer diese Responder sind, wieviele 
auf die Therapie ansprechen und wie wirksam die Therapie tatsächlich ist. 
Informationen zu den Nicht-Respondern fehlen ebenfalls. 
Der Effekt der Stimulationstherapie, der bei Respondern gezeigt wurde, war 
in einer anderen Studienpopulation, randomisiert in eine Kontrollgruppe 
ohne Aktivierung der Stimulation und in eine Behandlungsgruppe mit Akt-
vierung, nicht nachweisbar. Die zugrundeliegende Ursache für die Verbesse-
rung des Schweregrades der OSA, unabhängig von der Aktivierung der Sti-
mulation bleibt unklar.  
Die richtige PatientInnenauswahl dürfte essentiell für den Erfolg der Be-
handlung sein, aber exakte Kriterien für die PatientInnenauswahl fehlen, 
weil PatientInnencharakteristika von Therapierespondern nur ungenügend 
bekannt sind. Die vorliegenden Daten legen nahe, dass eine inkorrekte Pati-
entInnenauswahl eine große Limitation darstellen könnte. 
Insgesamt sieben Publikationen von 4 Fallserien entsprachen den Ein-
schlusskriterien zur Beurteilung der Sicherheit [16-21]. 
Schwere unerwünschte produktbezogene Ereignisse (SADE), wie Wundin-
fektionen, Elektrodenbrüche und Repositionierung des Neurostimulators 
traten in 2 % der PatientInnen auf, eine Explantation erfolgte in 2 % der 
Fälle in einem Beobachtungszeitraum von 40 Monaten. Studien mit kleinen 
Fallzahlen zeigten höhere Raten an schweren unerwünschten produktbezo-
genen Ereignissen und Explantationsraten bis 13 % in einem Beobachtungs-
zeitraum von 6 bzw. 12 Monaten. Todesfälle, die auf die Intervention zu-
rückzuführen waren, sind nicht aufgetreten. 
Unerwünschte Ereignisse (AE), wie Schmerzhaftigkeit, Läsionen und vo-
rübergehende Schwäche der Zunge, sowie Unbehagen aufgrund der elektri-
schen Stimulation waren häufig, 469 Ereignisse traten in 126 PatientInnen 
in einem Beobachtungszeitraum von 40 Monaten auf.  
Insgesamt ist die Stärke der Evidenz für die Effektivität und Sicherheit der 
Stimulation des Nervus hypoglossus im Vergleich zu keiner Behandlung als 
niedrig bis sehr niedrig einzuschätzen. Schwere unerwünschte produktbezo-
gene Ereignisse (SADE) traten relativ selten auf. Langzeitdaten zu Wirk-




Therapieentzugs nur  
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zu kardiovaskulären Erkrankungen und Mortalität als relevante Endpunkte 
bei OSA.  
Aktuell ist eine laufende randomisierte kontrollierte Studie registriert 
(NCT02263859). In der Studie wird das Aura6000™ System (ImThera Medi-
cal, Inc.) implantiert. Eine weitere randomisierte kontrollierte Studie mit 
einer verzögerten Aktivierung der Stimulationstherapie ist im Laufen, die 
Rekrutierung von 40 PatientInnen wird im Jahr 2016 abgeschlossen sein. In 
der Studie wird das Inspire® UAS System (Inspire Medical Systems, Inc.) 
implantiert. 
Die entscheidende Schwäche des vorliegenden Berichts liegt in der Unvoll-
ständigkeit der verfügbaren Informationen über die Studie, die vom Unter-
nehmen vorzeitig nach einer negativen Interimsanalyse beendet wurde. 
Trotzdem entschieden wir den RCT zu inkludieren um ein selektives Be-
richten zu verhindern. Allerdings war es nicht möglich anhand der im 
Abstract angegebenen Informationen das Bias-Risiko zu beurteilen. Inwie-
weit das eine Änderung in der Einschätzung ergeben hätte, ist unklar, die 
Möglichkeit wird aber als gering erachtet. 
 
Empfehlung  
Die gegenwärtige Studienlage lässt keine Rückschlüsse zu, ob eine Behand-
lung der mittel-bis schwergradigen OSA mittels Stimulation des Nervus hy-
poglossus wirksamer oder gleich sicher ist als die Vergleichsintervention 
„keine Behandlung“.  
Neue Studien werden möglicherweise einen wichtigen Einfluss auf die Ein-
schätzung des Effekts haben. Eine neuerliche Evaluierung wird im Jahr 
2018 vorgeschlagen, da Ergebnisse aus neuen RCTs vorliegen werden. Die 
Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen.  
 







Re-evaluierung für  
2018 empfohlen 
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1 Scope 
1.1 PICO question 
Is hypoglossal cranial nerve stimulation in comparison to no treatment in 
adult patients with moderate-to-severe obstructive sleep apnea, who do not 
accept or have failed to comply with CPAP treatment, effective and safe con-
cerning reduction in OSA severity, daytime sleepiness, quality of life and se-
rious adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Adult patients with moderate-to-severe obstructive sleep apnea,  
[“Sleep Apnea, Obstructive“]  
Either not accepting or not adhering to CPAP therapy [“Continuous Positive 
Airway Pressure“] or have failed conservative treatment 
First/second line treatment 
Intervention Hypoglossal cranial nerve stimulation (HNS)  
[“Electric Stimulation Therapy“]  
Control No stimulation treatment3 
Outcomes  
Efficacy Severity of obstructive sleep apnea (Apnea- hypopnea index;  
the number of apnea and hypopnea events per hour of sleep) 
Level of daytime sleepiness (e.g. Epworth Sleepiness Scale) 
Quality of life 
Safety Serious adverse device effect (SADE) 
Serious adverse events (SAE) 
Adverse events (AE) 
Study design  
Efficacy Randomised controlled trials 
Safety Randomised controlled trials 
Prospective case-series  
[with at least 10 patients, length of follow-up at least 6 months] 
Registries with more than 100 patients 
 
                                                             
3
 Although CPAP therapy is the first line therapy in moderate-to-severe obstructive 
sleep apnea, a control group of therapeutic CPAP users is impractical because only 




für relevante Studien 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is hypoglossal nerve stimulation and the comparator(s)?  
A0020 For which indications has hypoglossal nerve stimulation received marketing authorisation or 
CE marking? 
B0002 What is the claimed benefit of hypoglossal nerve stimulation in relation to the 
comparator(s)? 
B0003 What is the phase of development and implementation of hypoglossal nerve stimulation and 
the comparator(s)? 
B0004 Who administers hypoglossal nerve stimulation and in what context and level of care is it 
provided? 
B0008 What kind of special premises are needed to use hypoglossal nerve stimulation? 
B0009 What supplies are needed to use hypoglossal nerve stimulation? 
A0021 What is the reimbursement status of hypoglossal nerve stimulation? 
 
Health problem and Current Use 
Element ID Research question 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for OSA? 
A0004 What is the natural course of OSA? 
A0005 What are the symptoms and the burden of OSA for the patients? 
A0006 What are the consequences of OSA for the society? 
A0024 How is OSA currently diagnosed according to published guidelines and in practice? 
A0025 How is the OSA condition currently managed according to published guidelines and in 
practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is hypoglossal nerve stimulation utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of the technology on mortality? What is the expected beneficial effect of the technology on mortality? 
D0005 How does hypoglossal nerve stimulation affect symptoms and findings (severity, frequency) 
of the disease or health condition? 
D0006 How does hypoglossal nerve stimulation affect progression (or recurrence) of the disease or 
health condition? 
D0011 What is the effect of hypoglossal nerve stimulation on patients’ body functions? 
D0016 How does the use of hypoglossal nerve stimulation affect activities of daily living? 
D0012 What is the effect of hypoglossal nerve stimulation on generic health-related quality of life? 
D0013 What is the effect of hypoglossal nerve stimulation on disease-specific quality of life? 
D0017 Were patients satisfied with hypoglossal nerve stimulation? 
Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea 
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Safety 
Element ID Research question 
C0008 How safe is hypoglossal nerve stimulation in comparison to the comparator(s)? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of hypoglossal nerve stimulation? 
C0007 Are the technology and comparator(s) associated with user-dependent harms? 





Description of the technology 
 Systematic literature search in Medline via Ovid, Embase, the 
Cochrane Library plus CRD (DARE, NHS-EED, HTA): see Section 
2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals 
 Handsearch for guidelines  
Health problem and Current Use 
 Systematic literature search in Medline via Ovid, Embase, the 
Cochrane Library plus CRD (DARE, NHS-EED, HTA): see Section 
2.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals 
 Handsearch for guidelines 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 18th and 21st of  
December 2015 in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to clinical trials in Medline and Embase. 
After deduplication, overall 180 citations were included. The specific search 
strategy employed can be found in the appendix.  
Quellen 
systematische 
Literatursuche in  
vier Datenbanken  
Methods 
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Manufacturers from two products (Inspire Medical Systems, Inc., ImThera 
Medical Inc.) submitted 21 publications of which 1 new citation was identi-
fied. By hand-search (Scopus), an additional 22 were found, resulting in 
overall 223 hits. 
2.4 Flow chart of study selection 
Overall 223 hits were identified. The references were screened by two inde-
pendent researchers (ISF, AK) and in case of disagreement a third research-
er was involved to solve the differences. The selection process is displayed in 
Figure 2-1. Articles that were excluded due to several reasons but still used 
as background are categorised under “background literature”. Furthermore, 
we were not able to order 1 article, categorised under “not available”. 
 







Records identified through 


























 Additional records identified 
through other sources  
(n=43) 
Records after duplicates  
removed  
(n=216) 




Full-text articles  
assessed for eligibility 
(n=30) 




 Background literature (n=3) 
 Wrong format (n=12) 
 Wrong intervention (n=1) 
 Wrong study design (n=2) 
 Double publication (n =1) 
 Wrong topic (1) 
 Not available (n=1) 
Studies included in 
qualitative synthesis 
(n=9) 
 RCTs (n=2) 
 Case-series (n=7) 
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2.5 Analysis 
The relevant information from the feasible studies was retrieved without any 
further analysis. For all studies the methodological quality was assessed by 
two independent researchers (ISF, AK) using a standardized risk of bias as-
sessment tool [22] and a checklist for case series [23]. The risk of bias analy-
sis for each individual study is shown in the Appendix (Chapter “Risk of 




The questions were answered in plain text format. In addition, evidence ta-
bles are used to show relevant information on the individual studies. Based 
on the evidence tables, data on each selected outcome category were synthe-
sised across studies according to GRADE (Grading of Recommendations As-
sessment, Development and Evaluation) [24] Table 7-1.  
The analysis of efficacy data is qualitative and not quantitative due to heter-
ogeneity of the data. The analysis of safety related data is qualitative and not 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is hypoglossal nerve stimulation and the comparator(s)? 
A number of factors contribute to OSA pathogenesis, including decreased 
tone during sleep in the upper airway dilator muscles, e.g. the genioglossus 
[5]. This notion has led to investigations of electrical stimulation of gen-
ioglossus using intramuscular or transcutaneous electrodes. But muscle 
stimulation led to disrupted sleep because of sensory phenomena [11-13]. As 
a result, direct electrical stimulation of the motor nerve innervating the gen-
ioglossus muscle, the hypoglossal nerve (HGN), has been explored as an al-
ternative [6-8]. Hypoglossal nerve stimulation involves a surgical procedure 
for device implantation. Stimulation of the HGN causes contraction of both 
the retrusor (styloglossus and hyoglossus) and the protrusor (genioglossus) 
muscles of the tongue thus maintaining an open airway during sleep.  
Currently, two products of hypoglossal nerve stimulation implants  
are marketed by two manufacturers  
 Inspire® Upper Airway Stimulation (UAS) System  
(Inspire Medical Systems, Inc.) 
 Aura6000™ System (ImThera Medical, Inc.) 
A third product is not available anymore 
 HNS/HGNS® System (Apnex Medical, Inc.) 
A fourth product is an investigational device, not for sale in Europe or US 
 Nyxoah SAT System (Nyxoah) 
Technical description of HGNS Systems 
 Inspire® Upper Airway Stimulation (UAS) therapy consists of a 
breathing sensor and a stimulation lead, powered by a small battery, 
which are both implanted. The breathing sensor is a pulmonary pres-
sure sensor to sense respiration. The neurostimulator delivers electri-
cal stimulating pulses to the hypoglossal nerve through the stimula-
tion lead; the stimulating pulses are synchronised with ventilation 
detected by the sensing lead. The system delivers mild stimulation to 
key airway muscles.  
 Aura6000TM System (ImThera Medical, Inc.) consists of an implant-
ed pulse generator (IPG), a small implant containing the battery and 
stimulation system, and a multi-electrode lead with a silicone cuff 
housing six independent electrodes connected to the IPG. The six 
stimulating electrodes are radially in contact with the cylindrical 
body of the proximal hypoglossal nerve. The device stimulates multi-
ple muscles of the tongue compared with the other devices, which on-
ly stimulate the largest muscle.  
 HNS/HGNS® System (Apnex Medical, Inc.) senses respiration using 
two leads. A nerve cuff electrode on the distal end of the stimulation 
lead is implanted on a branch of the hypoglossal nerve in the sub-
mandibular region. The proximal end of the stimulation lead is tun-
neled under the skin to the Neurostimulator. The respiration sensing 
elektrische Stimulation 
des Nervus hypoglossus 
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leads are tunneled under the skin from the neurostimulator to the 
costal margins. Stimulation is generated by the neurostimulator, syn-
chronised with inspiration as measured by the respiration sensing 
leads using bio-impedance, and delivered to the hypoglossal nerve by 
the stimulation lead.  
Inspire® UAS and HNS/HGNS® Systems are technically similar in that 
both systems sense respiration. Aura6000TM Systems, unlike Inspire® UAS 
and HNS/HGNS® Systems do not have a mechanism to sense respiration.  
Table 3-1: Technical components of hypoglossal nerve stimulation systems 
 Inspire® Upper Airway 
Stimulation (Inspire Medical, Inc.) 
Aura6000TM System  
(ImThera Medical, Inc.) 
HNS/HGNS® System  










external remote control 
charger 
Right ipsilateral  
mid-infraclavicular 
region 
Stimulation lead Synchronised with ventilation  
cuff section with 3 electrodes 
multi-electrode lead  
6 independent electrodes 
Synchronised with 
inspiration detected by 
respiration sensing leads 
Respiration 
sensing lead  
Sensing side facing the pleura 
pulmonary pressure sensor 
- 2 leads detect inspiration 
using bio-impedance 
 
Common to all, a small handheld sleep remote is used by patients to turn 
stimulation therapy on at night before going to bed and off in the morning 
after waking up. The remote control charger to charge the battery in the Au-
ra6000TM System is also used to start and end each night session of stimula-
tion. 
Nyxoah is an ultra-small Neurostimulator that measure 20mm in diameter 
and is 2.5mm thick. It’s designed to be implanted close to the nerves of the 
tongue muscle by a single small incision. A fundamental difference to other 
neurostimulation devices is that the Nyxoah SAT System can monitor the 
tongue and stimulate the muscles only when it blocks the airway.
4
 The FDA 
has approved an investigational device exemption (IDE) for the clinical 
study NCT02312479. 
The comparator is ‘no treatment’ because only those patients who could not 
use CPAP, or who declined to do so, are the target group of the intervention. 
‘No treatment’ means that the device is implanted but not activated. Blind-
ing of patients was impossible because they have to turn simulation therapy 
on at night. Blinding of treating physicians was impossible as well. The 
stimulation settings were adjusted in an overnight sleep study, so called ti-
tration night, after a healing period of approximately 30 days after implanta-
tion. To potentially reduce information bias, subtherapeutic stimulation as 
sham treatment could be taken into consideration [14]. 
 
  
                                                             
4
 http://www.nyxoah.com/product, accessed 26022016  
Komparator: keine 
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A0020 – For which indications has hypoglossal nerve stimulation  
received marketing authorisation or CE marking? 
Inspire® Upper Airway Stimulation (UAS) therapy has received CE Mark 
approval in 2010 for the treatment of a subset of patients with moderate-to-
severe OSA. One contraindication for use is an unresolved complete concen-
tric collapse at the level of the soft palate.
5
 
In the US, FDA approved the device in 2014 to treat a subset of patients 
with moderate-to-severe OSA, AHI ≥20 and ≤65 in adult patients of 22 
years of age and older who have been confirmed to fail or cannot tolerate 
Positive Airway Pressure (PAP) treatments and who do not have a complete 
concentric collapse at the soft palate level.
6
 
The Aura6000TM System has received the European CE Mark approval in 
2012 for the treatment of OSA.
7
 
In 2014, FDA has approved an investigational device exemption (IDE) for 
the Aura6000TM System for the clinical study NCT02263859. Data from 




Apnex Medical, Inc. has received CE Mark approval for its HNS/HGNS® 
System in 2011 for use by people who suffer from obstructive sleep apnea. 
The system was approved for sale in Europe. Apnex Medical, Inc. received 
investigational device exemption (IDE) approval from the U.S. FDA to con-
duct a clinical study.
9
 Apnex Medical, Inc. officially ceased operations in 
March 2013 because of an unsuccessful clinical trial.
10
 
B0002 – What is the claimed benefit of hypoglossal nerve stimulation? 
The expected main benefit is a significant reduction in obstructive sleep ap-
nea as well as improvements in the quality of sleep and quality of life in 
OSA patients not accepting or tolerating CPAP.  
The benefit in overall health, cardiovascular morbidity and mortality needs 
to be scientifically confirmed in the long-term. 
B0003 – What is the phase of development  
and implementation of hypoglossal nerve stimulation? 
Clinical trials using hypoglossal nerve stimulation have been undertaken, 
clinical trial sites in Austria did not participate. 
                                                             
  
5
 Information from the dossier of Inspire provided for evaluation at LBI-HTA. 
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Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers hypoglossal nerve stimulation  
and in what context and level of care is it provided? 
See Element ID B0008 
B0008 – What kind of special premises  
are needed to use hypoglossal nerve stimulation? 
The implantation of HGNS system should be performed by a specialised 
otorhinolaryngologist experienced in the surgical technique and postopera-
tive management. The procedure is performed under general anaesthesia in 
an inpatient setting [21]. Prior to the implementation a drug-induced sleep 
endoscopy is needed. Prior to and after implantation full-night, in-
laboratory diagnostic polysomnographic examinations are required. It is ad-
vised that HGNS implantation is restricted to highly specialised centres like 
University hospitals. 
B0009 – What supplies are needed to use hypoglossal nerve stimulation? 
For implementation, a sterile operation theatre is needed. The operation it-
self requires a specialised otorhinolaryngologist with a supporting team as 
well as a physicist and equipment for neuromonitoring. Several instruments 
are needed for the intervention (knife for incisions, subcutaneous tunnelling 
device etc.). It is performed in an inpatient setting. A sleep laboratory and 
specialists in sleep medicine are required as well as an endoscopy unit. Ap-
plication of the HGNS device will require a more extensive clinical work-up 
for diagnostic purposes compared with the current situation. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status  
of hypoglossal nerve stimulation? 
Actually, the device implantation for hypoglossal nerve stimulation for the 
treatment of moderate-to-severe OSA is not included in the Austrian hospi-
tal benefit catalogue. Therefore, the intervention itself is not reimbursed by 
the Austrian health care system. 
 
Implantation durch 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
Obstructive sleep apnea (OSA) is caused by repetitive obstruction of the up-
per airway during sleep, resulting in hypopnea (reduced airflow during 
sleep) or apnea (complete airflow cessation during sleep) [25]. Airflow ob-
struction is thought to result from reduction in pharyngeal neuromuscular 
activity at sleep onset [26, 27]. Because of protective reflexes, the pharyngeal 
airway maintains patency during wakefulness, but, during sleep, loss of 
these reflexes reduces the activity of the pharyngeal dilator muscle, causing 
collapse of the susceptible airway [2]. Collapsibility can also be increased by 
underlying anatomic alterations. Obesity and particularly central adiposity, 
both potent risk factors for sleep apnea, can increase pharyngeal collapsibil-
ity through mechanical effects on pharyngeal soft tissues [1].  
The apnea-hypopnea index (AHI) is commonly used to categorize the severi-
ty of OSA and it represents the average number of apneas and/or hypopneas 
per hour of recorded sleep. In adults, an AHI of less than 5 events per hour 
is considered normal. Mild OSA is defined as an AHI between 5 and 15 
events per hour, moderate OSA between 15 and 30 events per hour, and se-
vere OSA as greater than 30 events per hour [28]. 
An apnea is defined as the complete cessation of airflow for at least 10 sec-
onds. Apneas are further classified as obstructive, central, or mixed, based 
on whether the effort to breathe is present during the event. A hypopnea is 
defined as a reduction in airflow that is followed by an arousal from sleep or 
a decrease in oxyhemoglobin saturation [3]. Commonly used definitions of a 
hypopnea require a 25% or 50% reduction in oronasal airflow associated ei-
ther with a reduction in oxyhemoglobin saturation or an arousal from sleep 
[29].  
A0003 – What are the known risk factors for OSA? 
Several risk factors, including obesity, male sex, age, and heritable factors, 
have been associated with an increased prevalence of obstructive sleep apnea 
in the general population [30]. Among these, obesity is one of the strongest 
sleep apnea risk factors [1]. Prevalence of OSA increases with age, particu-
larly in adults older than 60 years [31-34]. The growing rate of obesity also 
contributes to increasing OSA prevalence [35].  
A0004 What is the natural course of OSA? 
The natural course of the OSA disorder has been investigated only in a few 
studies [36]. Mild-to-moderate OSA has a tendency to worsen, although pa-
tients may improve or remain stable. OSA leads to excessive daytime sleepi-
ness, cognitive dysfunction, impaired work performance, and decrements in 
health-related quality of life, if left untreated. OSA is associated with ad-
verse clinical outcomes, including cardiovascular disease [3, 37-39], hyper-
tension [40-42], cognitive impairment and metabolic abnormalities, such as 
type 2 diabetes [3, 43-46]. OSA significantly increases the risk of death from 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What are the symptoms and the burden of OSA for the patient? 
Clinical symptoms include unintentional sleep episodes during wakefulness, 
daytime sleepiness, unrefreshing sleep, fatigue, insomnia, snoring and cog-
nitive impairment [49, 50]. OSA has been associated with diabetes, an in-
creased cardiovascular and cerebrovascular morbidity and mortality [51]. 
A0006 – What are the consequences of OSA for the society? 
Patients with OSA have higher rates of health care use, more frequent and 
longer hospital stays, and greater health care costs than after diagnosis [52, 
53]. Excessive daytime sleepiness in OSA has been related to an increased 
risk of accidents [54-56]. Observational studies indicate that CPAP reduces 
motor vehicle crash risk among drivers with OSA [57, 58]. 
 
Current clinical management of the disease or health condition 
A0024 – How is OSA currently diagnosed according  
to published guidelines and in practice? 
Polysomnography performed in a sleep laboratory has been the standard 
method to diagnose OSA [9, 49, 59]. 
A0025 – How is the OSA condition currently managed  
according to published guidelines and in practice? 
The goal of the OSA treatment is to alleviate airway obstruction during 
sleep. CPAP is currently the universally-accepted standard treatment for 
moderate-to-severe OSA. The CPAP machine delivers a positive stream of 
air pressure that acts as a pneumatic splint to maintain the opening of the 
airway during sleep. The intervention requires patients to wear a nasal or 
full face mask whilst sleeping. Compliance in the home setting is often poor, 
with only 40 to 60 per cent of patients using the treatment long-term or as 
prescribed. When adherence is defined as greater than 4 hours of nightly 
use, 46 to 83% of patients with obstructive sleep apnea have been reported to 
be nonadherent to treatment [60-62]. 
Other treatment options (oral appliance therapy, positional therapy, weight 
loss, and upper airway reconstructive surgery) are available for selected pa-
tients, but the treatment effect is frequently incomplete [63]. Upper airway 
surgery, a treatment option for carefully selected patients with OSA, aims at 
reducing anatomical upper airway obstruction in the nose, oropharynx and 
hypopharynx [22]. But long-term follow-up studies have suggested that the 
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Target population 
A0007 – What is the target population in this assessment? 
The target population are patients with moderate-to-severe OSA who do not 
tolerate CPAP and do not adhere to therapy for many reasons like discom-
fort, skin irritation, noise and claustrophobia [25, 64-66]. 
A0023 – How many people belong to the target population?  
Large population-based prevalence studies of predominately white popula-
tions estimate the prevalence of the OSA syndrome at approximately 3–4% 
in men and 2% in women [30, 32, 33, 67]. The OSA syndrome is character-
ised by both an AHI ≥5 along with daytime sleepiness [28]. In the Wiscon-
sin Sleep Cohort Study, the prevalence of OSA, based on an AHI of >15 in 
people aged 30 to 60 years, was 9.1% in men and 4.0% in women [30]. How-
ever, specific data for Austria are not available. 
There is no information available on how many patients with moderate-to-
severe OSA, not tolerating or not adhering to CPAP therapy, are potential 
candidates for HGNS therapy belonging to the subgroup of currently un-
treated patients.  
A0011 – How much are the technologies utilised? 
According to the description of the application form we received from the 
Austrian Ministry of Health (“Verwaltung von Änderungs- und Ergänzungs-
vorschlägen zum Leistungskatalog des BMG”, VAEV), the anticipated vol-
ume of implanted devices is estimated at 15 per year while 3 procedures 
were performed in the past year. The given information applies only to the 
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3-4 % bei Männern,  
2 % bei Frauen 
erwartet:  
15 Eingriffe/Jahr  
(1 Krankenanstalt) 
 LBI-HTA | 2016 31 
5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Severity of obstructive sleep apnea (AHI) 
 Level of daytime sleepiness (e.g. Epworth Sleepiness Scale) 
 Quality of life 
Cardiovascular morbidity and mortality are relevant clinical endpoints that 
were not taken into consideration given the early phase of development of 
HGNS. 
AHI is an index used to indicate the severity of sleep apnea. It is represented 
by the number of apnea and hypopnea events per hour of sleep. AHI is one 
of several sleep study measures in polysomnography, but it is not a clinical 
or health outcome. In adults, an AHI less than 5 events per hour is consid-
ered normal. Mild OSA is defined as an AHI between 5 and 15 events per 
hour, moderate OSA between 15 and 30 events per hour, and severe OSA as 
greater than 30 events per hour [28]. In studies, the reduction of more than 
50% and less than 20 has been defined as a clinically meaningful improve-
ment of AHI. 
There were no studies addressing health outcomes like cardiovascular mor-
bidity or mortality. However, AHI greater than 30 events per hour is an in-
dependent predictor of all-cause mortality, but the evidence is insufficient 
regarding the association between AHI and other clinical outcomes [68].  
The Epworth Sleepiness Scale [69] is a validated subjective measure of sleep 
propensity. The ESS differentiates between average sleepiness and excessive 
daytime sleepiness and focuses solely on sleepiness and no other signs and 
symptoms of OSA. The ESS asks people to rate their usual chances of dozing 
off or falling asleep in 8 different situations or activities that most people 
engage in as part of their daily lives, although not necessarily every day. 
Based on a study of normal subjects, the reference range is defined as ≤10 
[70, 71]. Data show that “normal” adults who do not have evidence of a 
chronic sleep disorder (including snoring) have a mean ESS score of 4.6 
(95% CI 9-5.3) with a SD of 2.8 [59]. A higher score indicates an increased 
risk to fall asleep during daily activities. 1 point change in ESS is considered 
to be clinically significant.  
The Functional Outcomes of Sleep Questionnaire (FOSQ), a disease specific 
quality-of-life measure, assesses the impact of disorders of excessive sleepi-
ness (DOES) on functional outcomes relevant to daily behaviours and quali-
ty of life. The potential range of scores for the total score is 5-20, where a 
higher score implies better subjective sleep quality. 2.0 points increase is 
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5.2 Included studies 
Study and patient characteristics 
For evaluating efficacy-related outcomes we called for RCTs. We identified 
two RCTs, one with a therapy withdrawal design [14] of a consecutive cohort 
of treatment responders (randomised subset) from a prospective single arm 
study of 126 implanted participants [16]. After completion of the 12-month 
follow-up, the first 46 therapy responders entered the withdrawal study. Par-
ticipants were randomised to either therapy maintenance (‘‘ON’’) group or 
therapy withdrawal (‘‘OFF’’) group for a minimum of 1 week. Another RCT 
[15], a multicentre study, was prematurely closed by the company following 
an unfavourable interim analysis after 6 months. Participants were random-
ly allocated on a 2:1 basis to have the device activated 1 month or 7 months 
postimplantation. The 6 month results from 21 patients from an Australian 
centre were reported in an abstract only. Although unconventional, we in-
cluded the abstract to avert selective reporting and due to limited infor-
mation, we refrained from assessing the risk of bias.  
Both studies with a total of 67 participants reported outcomes at 6 months, 
the withdrawal study reported also outcomes after 1 week of therapy 
maintenance and therapy withdrawal. The mean age of patients ranged from 
53 and 57 years. The minority of patients were females (11-19%), the loss to 
follow-up rate was 0%. The inclusion criteria differed between the two stud-
ies; the withdrawal study included only therapy responders with at least 50% 
reduction of AHI from baseline and AHI less than 20 events per hour. Orig-
inally, patients included in the single arm study [16] had to have an AHI 
>20 to 50 events per hour without a complete concentric collapse at the ret-
ropalatal airway observed in DISE, whereas the second RCT included par-
ticipants with an AHI of 20 to 80 events per hour. 
Inspire® UAS System was implanted in the withdrawal study [14], HNS/ 
HGNS® System in the other trial [15]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table 7-1. Due to insuffi-
cient information, we could not assess the risk of bias of the RCT reported 





D0001 – What is the expected beneficial effect of hypoglossal nerve 
stimulation on mortality? 
Cardiovascular and all-cause mortality is a relevant outcome for assessing 
the clinical effectiveness of hypoglossal nerve stimulation in treating moder-
ate-to-severe OSA. Due to the lack of long-term studies, the effectiveness on 
mortality is unknown. No evidence was found to answer the research ques-
tion. 
 
2 RCTs identifiziert: 
 





1 RCT zu Inspire® mit 




Alter 53–57 Jahre, 
mehrheitlich Männer 
keine Evidenz zu 
Endpunkt Mortalität 
Clinical effectiveness 
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Morbidity 
D0005 – How does hypoglossal nerve stimulation affect symptoms  
and findings (severity, frequency) of moderate-to-severe OSA? 
Answering this research question was based on the outcomes “AHI” and 
“ESS”. The difference in AHI and ESS was reported in both RCTs [14, 15]. 
After 1 week, the AHI in the “on-treatment” group was statistically signifi-
cant, lower [-16.9 (95% CI -24.7, -9.0)] than in the “off treatment” group 
[14]. Both groups consisted only of treatment responders. After 6 months, 
the treatment was resumed in both groups, the AHI showed no statistically 
significant difference between groups [14]. In contrast, after 6 months, the 
AHI showed no statistically significant difference between the “device ac-
tive” and the control group in previously “treatment naïve” participants 
[15].  
Data regarding AHI are valid only for a short period of 6 months but not in 
the long-term.  
After 1 week, the ESS in the “on-treatment” group was lower [-4.5 (95% CI -
7.5, -1.4)] than in the “off treatment” group, which was statistically signifi-
cant [60]. After 6 months, the treatment was resumed in both groups and the 
ESS showed no statistically significant difference between groups [60]. In 
contrast, after 6 months, the ESS showed no statistically significant differ-
ence between the “device active” and the control group in previously “treat-
ment naïve” participants [62]. 
D0006 – How does hypoglossal nerve stimulation affect progression  
(or recurrence) of moderate-to-severe OSA? 
Answering this research question was based on the “AHI” outcome in both 
RCTs. See Element ID D0005.  
 
Function 
D0011 – What is the effect of hypoglossal nerve stimulation  
on patients’ body functions? 
Moderate-to-severe OSA affects the cardiovascular system and is associated 
with diabetes and cognitive impairment. Thus, answering this research ques-
tion is relevant but has been defined as not feasible. No evidence was found 
to answer the research question. The effect of hypoglossal nerve stimulation 
on functioning has not been studied.  
D0016 – How does the use of hypoglossal nerve stimulation  
affect activities of daily living? 
The treatment with HGNS affects daytime sleepiness in daily life activities 
and functional outcomes relevant to daily behaviours in moderate-to-severe 
OSA. See Element ID D0005 and Element ID D0013. 
 
Health-related quality of life 
D0012 – What is the effect of hypoglossal nerve stimulation  
on generic health-related quality of life? 
No evidence was found to answer this research question (no identified study 
reported generic health-related quality of life). 
Endpunkte AHI, ESS: 
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D0013 – What is the effect of hypoglossal nerve stimulation  
on disease-specific quality of life? 
The disease specific quality of life was reported in one RCT [14]. After 1 
week, the FOSQ in the “on treatment” group was increased in a statistically 
significant way by 2.9 (95% CI 0.8, 5.0) compared to the “off-treatment” 
group (2.0 points increase is considered a minimally important difference). 
After 6 months, the treatment was resumed in both groups, the FOSQ 
showed no statistically significant difference between groups. 
 
Patient satisfaction 
D0017 – Were patients satisfied with the hypoglossal nerve stimulation? 
To answer this research question, the outcome “FOSQ” was used. The effect 
of HGNS on disease specific quality of life has already been addressed in the 




QoL eine Woche nach 
Therapieentzug in 
Therapierespondern 
 LBI-HTA | 2016 35 
6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Adverse events (AE) 
 Serious Adverse Events (SAE) 
 Serious adverse device effects (SADE) 
In accordance with the guidelines of medical devices on serious adverse 
event reporting, these outcomes have been selected.
11
  
Adverse Event (AE) is any untoward medical occurrence, unintended dis-
ease or injury or any untoward clinical signs (including an abnormal labora-
tory finding) in subjects, users or other persons whether or not related to the 
investigational medic al device. This includes events related to the investiga-
tional device or related to the procedures involved (any procedure in the 
clinical investigation plan).  
Serious Adverse Event (SAE) is an adverse event that led to a death, to a se-
rious deterioration in health of the subject that either resulted in a life-
threatening illness or injury, or a permanent impairment of a body structure 
or a body function. Alternatively, an event that led to in-patient hospitalisa-
tion or prolongation of existing hospitalisation, or medical or surgical inter-
vention to prevent life threatening illness or injury. 
Serious Adverse Device Effect (SADE) is an adverse event related to the use 
of an investigational medical device that has resulted in any of the conse-
quences characteristic of a serious adverse event. First, this includes any ad-
verse event resulting from insufficiencies or inadequacies in the instructions 
for use, deployment, implantation, installation, operation, or any malfunc-
tion of the investigational medical device. Second, this includes any event 
that is a result of a use error or intentional abnormal use of the investiga-
tional medical device. 
 
 
6.2 Included Studies 
Study and patient characteristics 
For evaluating safety-related outcomes, we accepted RCTs, prospective case-
series with more than 10 patients and length of follow-up of more than 6 
months, and registries with more than 100 patients. 
However, we could not identify any controlled trials reporting safety out-
comes of hypoglossal nerve stimulation for the treatment of moderate-to-
severe OSA. The only studies that met our inclusion criteria are seven sin-
gle-arm studies with a total of 224 patients assessing the safety of hypoglos-
sal nerve stimulation [16-21, 72].  
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The mean age of patients differed between 50 and 55 years [21] [16]. The 
minority of patients was females (3-35%) [20, 72]. The follow-up of studies 
was 6 months [19, 72], 12 months up to 20 months [16, 17, 20, 21] and 36 
months (3 years) [18]. The loss to follow-up rate differed between 2 and 11% 
[16, 72].  
One trial reported safety outcomes at 12 months [16], at 18 months [17], and 
36 months [18] for 126 patients. One trial reported safety outcomes at 6 
months for 21 patients [19] and at 12 months for 32 patients (including 21 
patients from [19]) [20]. 
Inspire® UAS Systems (Inspire Medical, Inc.) were implanted in two trials 
with 4 publications [16-18, 72], HNS/HGNS® Systems (Apnex Medical, 
Inc.) were implanted in one trial with 2 publications [19, 20] and Au-
ra6000TM Systems (ImThera Medical, Inc.) were implanted in one trial 
[21]. 
All studies included patients with moderate-to-severe OSA with failure or 
intolerance of CPAP treatment. One trial included patients with an AHI be-
tween 20 and 100 per hour, with ≥15/h occurring in NREM sleep and a pre-
dominance of hypopneas (≥80%) as a proportion of the sum of apnea and 
hypopnea events [19, 20]. One study included patients with AHI ≥25/h in 
the first part, in the second part only selected patients based on predictors of 
therapy response in Part 1 were included (AHI between 20-50/h, without 
complete concentric collapse at the level of soft palate, determined by drug-
induced sleep endoscopy) [72]. One study included patients with AHI ≥20/h 
and no preferential selection of subjects for apnoea or hypopnoea indices 
[21], but excluded patients with clinically enlarged tonsils (grade 3 or 4) and 
the presence of obstructive nasal polyps. One trial included patients with an 
AHI greater than 20 to 50/h without complete concentric collapse at the ret-
ropalatal airway observed in DISE [16-18].  
Study characteristics and results of included studies are displayed in Table 





C0008 – How safe is hypoglossal nerve stimulation  
in comparison to the comparator(s)? 
No studies were identified that are directly comparing hypoglossal nerve 
stimulation for the treatment of OSA with no intervention. 
In the single-arm studies, serious adverse device effects (SADE) occurred in 
7-10% of patients, the device was explanted in 6-7% of patients at 6 months 
[19, 72]. At 12-20 months, SADE occurred in 2-23% of patients, the device 
was explanted in 1-13% of patients [16, 20, 21]. At 40 months, SADE oc-
curred in 2% of patients, the device was explanted in 2% of patients [18]. Se-
rious adverse device effects included adverse events like infection, device 
explantation, cuff dislodgement, spinal accessory nerve damage, broken 
leads, defective pulse generator and device revision, but no deaths occurred. 
Alter im Durchschnitt 
50–55 Jahre, 
mehrheitlich Männer, 
Follow-Up bis 3 Jahre 
2 Studien  
(4 Publikationen)  
zu Inspire® 
 
eine Studie  
(2 Publikationen)  
zu HNS/HGNS® 
eine Studie zu 
Aura6000™  
 
Population in allen 
Studien: mittel- bis 
schwergradige OSA 





SADE 2–23 % 
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Overall adverse events (procedure or device/therapy-related) are not report-
ed in percentage of patients, but only in terms of events per study popula-
tion. Because of unclear reporting, data may be imprecise.  
At 6 months, 15 events occurred in 31 patients, respectively 66 events in 21 
patients [19, 72]. At 12 to 18 months, 64 events occurred in 14 patients, re-
spectively 392 events in 126 patients [17, 21]. 469 events occurred in 126 pa-
tients at 40 months [18]. Very frequently occurring upcoming events were 
discomfort due to electrical stimulation, tongue abrasion, tongue soreness, 
temporary tongue weakness and post-operative discomfort related to inci-
sions. 
Serious adverse events (SAE) (procedure or device/therapy-related) occurred 
in 10-14% of patients at 6 months [19, 72], at follow-up 12-18 months, rates 
ranged from 21 to 29% [17, 21].  
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No direct evidence was found to answer this research question in an appro-
priate way. 
However, it seems likely that the frequency and/or severity of harms de-
crease over time. The identified study with the longest duration and the 
most patients reported 343 adverse events in the first year, 49 in the follow-
ing 6 months and 77 in the following 22 months [18]. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of hypoglossal nerve stimulation? 
No direct evidence was found to answer this research question. 
C0007 – Is hypoglossal nerve stimulation associated with  
user-dependent harms? 
No direct evidence was found to answer this research question. However, in 
all included studies, hypoglossal nerve stimulation was implanted by experi-
enced specialised otolaryngologists. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed to monitor 
the use of hypoglossal nerve stimulation? 
No literature was retrieved that identified specific data or monitoring rec-
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) Schema [24] for 
each endpoint individually. Each study was rated by two independent re-
searchers (ISF, AK). In case of disagreement a third researcher was involved 
to solve the difference. A more detailed list of criteria applied can be found 
in the recommendations of the GRADE Working Group [24].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit a 
conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall the strength of evidence for the effectiveness and safety of hypoglos-
sal nerve stimulation is low to very low.  
 
 

























Table 7-1: Evidence profile: efficacy and safety of hypoglossal nerve stimulation in patients with moderate-to-severe obstructive sleep apnea  
No of studies/ 
patients Study Design Estimate of effect 
Study  





Efficacy: HNS stimulation vs no stimulation 
Apnea-hypopnea index (AHI) (difference between groups) 
2/67 RCT 1: withdrawal design, only 
responders included, control group 
device off for 1 week 
RCT 2: device implanted, control 
group device not activated 
Difference between groups:  
after 1 week: -16.9 (s.s.)  







Imprecise data  
(-1)14 
Very low 
Oxygen Desaturation Index (ODI) (difference between groups) 
2/67 RCT 1: withdrawal design, only 
responders included, control group 
device off for 1 week 
RCT 2: device implanted, control 
group device not activated 
Difference between groups:  
after 1 week: -15.1 (s.s.)  







Imprecise data  
(-1)14 
Very low 
Functional Outcomes of Sleep Questionnaire (FOSQ) (difference between groups) 
1/46 RCT 1: withdrawal design, only 
responders included, control group 
device off for 1 week 
Difference between groups:  
after 1 week: 2.9 (s.s.) 
Serious 
limitations (-1)12 
n/a (only 1 trial) Some 
uncertainty (-1)13 
Imprecise data  
(-1)14 
Low 
Epworth Sleepiness Scale (ESS) (difference between groups) 
2/67 RCT 1: withdrawal design, only 
responders included, control group 
device off for 1 week 
RCT 2: device implanted, control 
group device not activated 
Difference between groups:  
after 1 week: -4.5 (s.s.)  
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(-1)14 
Very low 
                                                             
12
 Randomisation and allocation concealment unclear 
13 RCT 1 included only responders to the treatment 
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s.s. = statistically significant; n.s. = not significant; mo = months; pts = patients 
 
 
                                                             
15
 The difference between the lowest and the highest percentage of system explants was more than 20% 
16
 Double counting of events possible because of unclear reporting 
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8 Discussion 
Obstructive sleep apnea (OSA) is caused by repetitive obstruction of the up-
per airway during sleep, resulting in hypopnea or apnea with intermittent 
hypoxia and transient arousals. Upper airway collapse during sleep is caused 
by an inadequate motor tone of the tongue and/or airway dilator muscles. 
Obesity and particularly central adiposity, both potent risk factors for sleep 
apnea, can also increase pharyngeal collapsibility through mechanical ef-
fects on pharyngeal soft tissues. OSA is associated with adverse clinical out-
comes, including cardiovascular disease, hypertension, cognitive dysfunc-
tion and metabolic abnormalities, such as type 2 diabetes as well as with an 
increased risk of traffic accidents. CPAP is currently the universally-
accepted standard treatment for moderate-to-severe OSA, but long-term 
compliance is limited and estimated to be in the order of 50%. Novel treat-
ments, like hypoglossal nerve stimulation, inducing substantial reduction of 
OSA may provide a possibility to treat a part of this subgroup of currently 
untreated patients.  
The aim of this report was to assess the clinical effectiveness and safety of 
hypoglossal nerve stimulation in patients with moderate-to-severe obstruc-
tive sleep apnoea refractory to CPAP. Two RCTs were available to assess the 
clinical efficacy of hypoglossal nerve stimulation in comparison to no inter-
vention. Seven case series were available to assess safety, since RCTs did not 
report any safety outcomes.  
Both RCTs included 67 patients with moderate-to-severe OSA but their in-
clusion criteria differed from each other [14, 15]. Responders in both trials 
were defined as achieving an AHI <20 with at least 50% reduction from 
baseline.  
One RCT had a withdrawal design [14]. After completion of 12-month fol-
low up in an uncontrolled prospective study [16], 46 consecutive patients, 
classified as ‘responders’, were selected and were randomly allocated to ei-
ther one week therapy-withdrawal subgroup or therapy-maintenance sub-
group. The a priori defined criteria for the single arm study excluded pa-
tients with a complete concentric collapse at the retropalatal airway ob-
served in drug-induced sleep endoscopy and therefore, this exclusion crite-
rion applies also to the randomised subgroup.  
It is unclear whether the second trial applied such exclusion criterion [15] 
because the only available information was from the registry, the database of 
clinical research studies 
17
 and a published abstract with study results of 21 
patients. The study has been terminated by the company following an unfa-
vourable interim analysis after 6 months. The intervention group was im-
planted with the HNS/HGNS® System (Apnex Medical, Inc.) and simula-
tion was turned on at 1 month post-implant. In the control group, likewise 
implanted with the system, therapy would have turned on at 7 months post-
implant. After six months, the efficacy-related outcomes failed to show a be-
tween-group difference in the reduction of OSA severity, owing to major un-
anticipated improvements in the control group. Both groups showed a con-
siderable reduction in AHI, but the underlying cause of improvement of 
AHI in the control group remains unknown. 
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The therapy-withdrawal RCT subgroup [14] discontinued the treatment for 
1 week. After 1 week, patients resumed the treatment for a six months fol-
low-up period, respectively an overall 18 months follow-up period. The with-
drawal of the stimulation therapy within 1 week resulted in worsening of all 
efficacy-related outcomes. When therapy was resumed, outcomes showed no 
difference between either of the groups at 18 months.  
Both RCTs are flawed by small sample sizes and the inherent lack of blind-
ing of hypoglossal nerve stimulation therapy. There is a high risk of bias in 
the withdrawal RCT associated with highly selected participants, not repre-
sentative of the population affected by OSA. Participants were recruited 
from an industry-sponsored, uncontrolled study and selected patients classi-
fied as ‘responders’ only for the trial population were included. Further-
more, a one week off therapy period does not allow long-term efficacy to be 
assessed [14].  
In highly selected responders, the effects of withdrawal and resuming the 
therapy were attributable to hypoglossal nerve stimulation. However, the 
study design and the selection of responders do not allow assessing the rela-
tive effectiveness of the intervention. As responders do not represent the tar-
get population in this report, the study results cannot be used as evidence to 
derive a recommendation.  
Furthermore, it is known that a subset of patients will respond to stimula-
tion therapy anyway, but who the responders are, how many of them will re-
spond and how effective hypoglossal nerve stimulation is remain unknown. 
And, important information about the non-responders is lacking.  
The effect of stimulation therapy shown in responders was not reproducible 
in another study population eligible for the stimulation therapy. The under-
lying cause of improvement of severity of OSA independent of active stimu-
lation remains unclear.  
Seven publications of four case series met our inclusion criteria to assess 
safety-related outcomes [16-21].  
The most prominent adverse events (AE) included tongue abrasions, tongue 
soreness or weakness and stimulation related discomfort. The most recent 
and largest study reported 469 adverse events in 126 participants at 40 
months. Both the rate of device-related and the rate of procedure-related ad-
verse effects are reported to decrease over time after implantation. More 
than half of the patients complained about discomfort due to electrical 
stimulation and one third about tongue abrasion, which required further ad-
justment of simulation parameters and dental adjustments [18].  
Serious adverse device effects (SADE) included wound infections, electrode 
fracture, lead and cuff dislodgement, defective pulse generator and device 
revision. The percentage of device explantations showed a high variability, 
ranging from 2% in the largest study [18] to 13% in a small study with 32 
participants [20], and it appears to depend on the appropriate technique ap-
plied, in particular, on the placement of stimulation electrodes. Device re-
lated deaths did not occur; three deaths, but classified as unrelated to the 
implantation, were reported at 40 months follow-up [18].  
Although the strength of evidence for safety is very low, hypoglossal nerve 
stimulation for treatment of OSA does not seem to be related with lethal 
consequences. However, it causes a high number of non-serious adverse 
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The influence of technical properties of different hypoglossal nerve stimula-
tion systems on the reported outcomes cannot be assessed, but appears to 
play a minor role. Appropriate patient selection appears to be essential for 
the success of therapy, but exact criteria for optimal patient selection are 
lacking because patient characteristics of responders are known incomplete-
ly. The available data may suggest that incorrect patient selection provides a 
major limitation.  
Additional parameters that might predict response and could then improve 
patient selection need to be determined. Data also suggest that hypoglossal 
nerve stimulation usually produces only a partial response and does not of-
fer a cure for the patient from the disease. 
Finally, the strength of evidence for efficacy and safety is low to very low re-
garding patient benefits and harms. Severe device-related adverse effects 
appear to be relatively rare. Information on device durability beyond 40 
months is lacking. Furthermore, long-term data regarding treatment effects, 
complications and compliance are lacking, and none of the relevant clinical 
endpoints like cardiovascular morbidity or mortality were reported.  
Currently, there is one registered ongoing randomised controlled trial 
(NCT02263859) with an open-label design for a four-month period. 
18
 Both 
groups will be implanted with the Aura6000™ System (ImThera Medical, 
Inc.). The estimated enrolment comprises 141 participants with a 12 month 
follow-up period. The primary completion is planned in May 2016, longer 
term data may become available as final completion is listed for May 2021. 
Another randomised controlled trial with delayed therapy activation with a 
6-month follow-up is mentioned in the dossier of the manufacturer provided 
for evaluation at LBI-HTA. Ongoing enrolment of 40 patients will be com-
pleted by 2016. Both groups will be implanted with the Inspire® UAS Sys-
tem (Inspire Medical, Inc.). The trial is not listed in the 3 databases with 
registered clinical trials. 
19
  
One major weakness of the systematic review is the incompleteness of avail-
able information on the study which has been terminated by the company 
following an unfavorable interim analysis. Nevertheless, we decided to in-
clude the RCT to avert selective reporting. But, due to limited information 
provided by the abstract only, we were not able to assess the risk of bias. The 
impact on the assessment is unclear, but the chance of modification is con-
sidered to be low.  
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with 
restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that hypoglossal nerve stimu-
lation for treating moderate-to-severe obstructive sleep apnea is more effec-
tive and equally safe than no treatment. New study results will potentially 
influence the effect estimate considerably.  
The re-evaluation is recommended in 2018.  
 
Evidenz derzeit  
nicht ausreichend  
für Empfehlung 
Re-evaluation 2018 
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Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Results from randomised controlled trials of HGNS for moderate-to-severe OSA 
Author, year Woodson et al. 2014 [14] Smart et al. 2013 [15] 
Country Germany, United States, The Netherlands Australia 
Study ID NCT01161420 (randomised subset) NCT0144660120 
Sponsor Inspire Medical, Inc. Apnex Medical, Inc. 
Intervention/Product Inspire® Upper Airway Stimulation (UAS) System HNS/HGNS® 
Comparator HNS off for one week and until 13-mo PSG was performed, then therapy resumed Device activated 7 mo post-implantation 
Study design Randomised Controlled Withdrawal Study RCT (allocated 2:1) 
Number of pts 46 21 
Inclusion criteria 1. Diagnosis of moderate-to-severe obstructive sleep apnea with difficulty accepting or 
adhering to CPAP treatment.  
2. BMI ≤32.0 
3.AHI ≥20-50/h 
4. Central or mixed sleep-disordered breathing events <25% of all apnea and hypopnea 
episodes 
5. Non-supine AHI >10/h  
6. No complete concentric collapse at the retropalatal airway observed in DISE 
Consecutive cohort of treatment responders (at least 50% reduction of AHI from baseline and 
AHI less than 20 events/hr), 12 months after device implantation 
Usual treatment options failed  
AHI 20-80 
Age of patients (yrs), Mean (SD) ON group 57.1 (10.0); OFF group 52.7 (10.4) 54.3 (1.7) 
Body mass index (kg/m2),  
Mean (SD) 
ON group 28.4 (2.4); OFF group 27.3 (2.4) NR 
Sex  ON group 22 male, 1 female; OFF group 19 male, 4 female 4 female, 17 male 
Follow-up (months) 6 months (after 12 mo followed from Strollo 2014, consecutive responders entered RCT) 6 months 
Loss to follow-up, n (%) 0 (0) 0 (0) 
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Author, year Woodson et al. 2014 [14] Smart et al. 2013 [15] 
Outcomes 
Efficacy (Hypoglossal nerve stimulation vs no stimulation) 
AHI, Mean (SD) ON group: Baseline (at 12 mo): 7.2 (5.0); after 1 week: 8.9 (9.1); Δ = 1.7 (6.4)  
OFF group: Baseline (at 12 mo): 7.6 (4.0); after 1 week [device off]: 25.8 (16.2); Δ = 18.2 (15.6)  
Difference between groups after 1 week: -16.9 (95% CI -24.7, -9.0) p<0.001 
ON group: 18 mo: 9.6 (11.3); OFF group: 18 mo [device on]: 10.7 (7.3)  
Difference between groups after 18 mo: -1.1 (95% CI -6.9, 4.7) p= 0.85 
Device active: Baseline: 34.1 (3.5); 6 mo: 22.1 
(5.2)  
Control: Baseline: 40.9 (6.5); 6 mo: 29.7 (6.2)  
Difference between groups at 6 months: n.s. 
Oxygen Desaturation Index, 
Mean (SD) 
ON group: Baseline (at 12 mo): 6.3 (5.4); after 1 week: 8.0 (8.9); Δ = 1.6 (5.8)  
OFF group: Baseline (at 12 mo): 6.0 (3.7); after 1 week [device off]: 23.0 (15.6); Δ = 17.0 (14.5)  
Difference between groups after 1 week: -15.1 (95% CI -22.7, -7.5) p<0.001 
ON group: 18 mo: 8.6 (11.0); OFF group: 18 mo [device on]: 9.1 (6.1)  
Difference between groups after 18 mo: -0.5 (95% CI -5.9, 5.0) p=0.86 
Device active: Baseline: 10.8 (2.5); 6 mo: 11.4 
(4.1)  
Control: Baseline: 22.2 (4.3); 6 mo: 19.5 (5.2)  
Difference between groups at 6 months: n.s.  
Difference at baseline between groups p<0.05 
Functional Outcome of Sleep 
Questionnaire, Mean (SD)21 
ON group: Baseline (at 12 mo): 17.9 (2.9); after 1 week: 17.9 (2.9); Δ = 0.0 (1.0)  
OFF group: Baseline (at 12 mo): 17.0 (3.5); after 1 week [device off]: 15.0 (4.0); Δ = 2.3 (3.0)  
Difference between groups after 1 week: 2.9 (95% CI 0.8, 5.0) p= 0.008 
ON group: 18 mo: 18.0 (2.9); OFF group: 18 mo [device on]: 17.1 (2.9)  
Difference between groups after 18 mo: 0.9 (95% CI -0.8, 2.6) p=0.29 
n.r. 
Epworth Sleepiness Scale,  
Mean (SD)22 
ON group: Baseline (at 12 mo): 5.9 (3.4); after 1 week: 5.6 (3.9); Δ = 0.3 (1.8)  
OFF group: Baseline (at 12 mo): 6.9 (4.6); after 1 week [device off]: 10.0 (6.0); Δ = -3.8 (4.6)  
Difference between groups after 1 week: -4.5 (95% CI -7.5, -1.4) p=0.005 
ON group: 18 mo: 6.0 (3.7); OFF group: 18 mo [device on]: 8.0 (4.4)  
Difference between groups after 18 mo: -2.0 (95%CI -4.5, 0.4) p=0.09 
Device active:  
Baseline: 11.1 (1.6); 6 mo: 9.8 (1.0)  
Control:  
Baseline: 13.6 (2.0); 6 mo: 14.1 (2.5)  
Difference between groups at 6 months: n.s. 
SD = Standard deviation, mo = months, yrs = years, n.r. = not reported; n.s. = statistically not significant; hr = hour;  
 
                                                             
21
 Functional Outcome of Sleep Questionnaire score range from 5 to 20, where a higher score implies better subjective sleep quality (2.0 points increase is considered a minimally important 
difference) 
22
 Epworth Sleepiness Scale range from 0-24, where a higher score indicates an increased risk to fall asleep during daily activities. Minimally important difference is not defined, but experts 













Table A-2a: Results from single-arm studies of HGNS for moderate-to-severe OSA (Apnex HNS/HGNS®) 
Author, year Eastwood et al. 2011 [19] Kezirian et al. 2014 [20] 
Study ID NCT01186926 
NCT01186926 
NCT01211444 
Country Australia, United States Australia, United States 
Sponsor Apnex Medical, Inc. Apnex Medical, Inc. 
Intervention/Product HNS/HGNS® HNS/HGNS®. 
Comparator No No 
Study design Multicenter, prospective single-arm interventional trial Multicenter, single arm, open label study 
Number of pts 21 32 (including 21 pts of Eastwood et al.) 
Inclusion criteria 1. Age from 21 to 70 years old.  
2. Diagnosis of moderate-to-severe OSA with failure of CPAP 
treatment.  
3. BMI ≤40kg/m2.  
4. AHI 20-100/h (≥15/h in NREM), ≥80% hypopneas  
as a proportion of the sum of apnea and hypopnea events. 
1. Age from 21 to 70 years old.  
2. Diagnosis of moderate-to-severe OSA with failure of CPAP 
treatment.  
3. BMI ≤ 40kg/m2.  
4. AHI 20-100/h (≥15/h in NREM), ≥80% hypopneas  
as a proportion of the sum of apnea and hypopnea events. 
Age of patients (yrs), Mean (SD) 53.6 (9.2) 52.4 (9.4) 
Body mass index (kg/m2), Mean (SD) 32.7 (3.6) 32.4 (3.6) 
Sex  14 male, 7 female 20 male, 11 female 
Follow-up (months) 6 12 
Loss to follow-up, n (%) 2 (10) 1 (3) 
Safety-related Outcomes 
Time since implantation 6 months 12 months 
Serious adverse events§, n (%) 3/21* (14) 9/31* (29) 
Death 0 0 
System explants  2 (1 elective removal before activation, 1 due to infection) 4 (1 elective removal before activation, 1 device infection,  
2 insufficient objective and subjective effectiveness) 
Infection 1 1 
Cuff dislodgement 1 2 
Spinal accessory nerve damage 1 1 
Readmission to hospital for psychological 
disturbance 
0 1 
Serious adverse device effects (SADE), 
n(%) 
2/21 (10) 3/31 (10) 
Adverse events§, n (%) 66 events¥; 12/21* (57) £ Number of events n.r.; 22/31* (71) £ 
§ System (device or therapy) or procedure-related * Totals refer to number of patients with an event (i.e., one subject may have had >1 event of a given severity); ¥ double counting of events possible 























Table A-2b: Results from single-arm studies of HGNS for moderate-to-severe OSA (Inspire® Upper Airway Stimulation System) 
Author, year Strollo et al. 2014 [16] Strollo et al. 2015 [17] Woodson et al. 2016 [18] Van de Heyning et al. 2012 [72] 
Study ID NCT01161420 n.r. 
Country Germany, Belgium, United States,  
The Netherlands 
Germany, Belgium, United States,  
The Netherlands 
Germany, Belgium, United States,  
The Netherlands 
USA, Germany, Belgium, Israel 
Sponsor Inspire Medical, Inc. Inspire Medical, Inc. Inspire Medical, Inc. Inspire Medical, Inc. 
Intervention/Product Inspire® Upper Airway  
Stimulation System 
Inspire® Upper Airway  
Stimulation System 
Inspire® Upper Airway  
Stimulation System 
HNS/Inspire II Upper Airway 
Stimulation (UAS) System 
Comparator No No No No 
Study design Multicenter, prospective,  
single-group, cohort design 
Multicenter, prospective,  
single-group, cohort design 
Multicenter, prospective,  
single-group, cohort design 
Multicenter, prospective  
single arm study 
Number of pts 126 126 126 31 (Part 1: 22; 2 excluded;  
Part 2: 9; 1 excluded) 
Inclusion criteria 1. Diagnosis of moderate-to-severe 
obstructive sleep apnea with 
difficulty accepting or adhering to 
CPAP treatment.  
2. BMI ≤32.0 
3. AHI ≥20-50/h 
4. Central or mixed sleep-disordered 
breathing events <25% of all apnea 
and hypopnea episodes 
5. Non-supine AHI >10/h 
6. No complete concentric collapse 
at the retropalatal airway observed 
in DISE 
1. Diagnosis of moderate-to-severe 
obstructive sleep apnea with 
difficulty accepting or adhering to 
CPAP treatment.  
2. BMI ≤32.0 
3. AHI ≥20-50/h 
4. Central or mixed sleep-disordered 
breathing events <25% of all apnea 
and hypopnea episodes 
5. Non-supine AHI >10/h 
6. No complete concentric collapse 
at the retropalatal airway observed 
in DISE 
1. Diagnosis of moderate-to-severe 
obstructive sleep apnea with 
difficulty accepting or adhering to 
CPAP treatment.  
2. BMI ≤32.0 
3. AHI ≥20-50/h 
4. Central or mixed sleep-disordered 
breathing events <25% of all apnea 
and hypopnea episodes 
5. Non-supine AHI >10/h 
6. No complete concentric collapse 
at the retropalatal airway observed 
in DISE 
Part 1: moderate-to-severe OSA, 
failed or were intolerant of CPAP 
treatment 
BMI <35 kg/m2 
AHI ≥25/h 
Part 2: moderate-to-severe OSA, 
failed or were intolerant of CPAP 
treatment, prospectively selected 
based on predictors of therapy 
response in Part 1 
BMI ≤32 kg/m2 
AHI 20-50/h 
Pts. without complete concentric 
collapse at the level of soft palate 
(determined by DISE) 
Age of patients (yrs),  
Mean (SD) 
54.5 (10.2) 54.5 (10.2) 54.5 (10.2) Part 1: 55.7 (8.1)  
Part 2: 53.6 (11.9) 
Body mass index (kg/m2), 
Mean (SD) 
28.4 (2.6) 28.4 (2.6) 28.4 (2.6) Part 1: 55.7 (8.1)  
Part 2: 53.6 (11.9) 
Sex  104 male, 22 female 104 male, 22 female 104 male, 22 female Part 1: 20 male 
Part 2: 7 male, 1 female 
Follow-up (months) 12 18 36 6 
Loss to follow-up, n (%) 2/126 (1.6) 3/126 (2.3) 10/126 (8) Part 1: 2/22 (9)  














Author, year Strollo et al. 2014 [16] Strollo et al. 2015 [17] Woodson et al. 2016 [18] Van de Heyning et al. 2012 [72] 
Safety-related Outcomes 
Time since implantation (SD) 12 months 12 to 18 months Total for an average of 40 (6) 
months 
6 months 
Serious Adverse Events 
(SAE), n (%)  
35 events, 27/126* (21), [reported for an average of 20 months,  
Strollo et al. 2014 Supplementary Appendix Table S1] 
n.r. Part 1: 2/21* (10); Part 2: 1/9* (11) 
Death, unrelated 2 (2) 3 (1cardiac event, 1 homicide,  
1 cardiac arrest after fall) 
0 
Other unrelated 31 events, 23/126* (18) n.r. 2 
Serious Adverse Device 
Effect (SADE), n (%)  
2 device revisions, 2/126* (2), [reported for an average of 20 months,  
Strollo et al. 2014 Supplementary Appendix Table S1] 
3 events, 3/126* (2) 2/30 (7) 
System explants 1 elective explant 3 (2 elective explant,  
1 device-unrelated septic arthritis) 
1 
System (device or therapy) 
or procedure-related adverse 
events, n (%) 
343 events, number of pts n.r.  
[Strollo et al. 2015 Table S1] 
49 events, number of pts n.r.  
[Strollo et al. 2015 Table S1] 
469 events, number of pts n.r. 
[Woodson et al. 2016 
Supplementary Appendix Table S1] 
15 events, number of pts n.r. 
* Totals refer to number of patients with an event (i.e., one subject may have had >1 event of a given severity); DISE = drug-induced sleep endoscopy; pts = patients; n.r. = not reported;  
SD = Standard deviation; yrs = years 
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Table A-2c: Results from single-arm studies of HGNS for moderate-to-severe OSA (ImThera Aura6000™) 
Author, year Mwenge et al. 2013 [21] 
Study ID NCT01532180 
Country Belgium 
Sponsor ImThera Medical, Inc. 
Intervention/Product Aura6000TM 
Comparator No 
Study design Open-label, single-site, single-arm interventional trial 
Number of pts 14 
Inclusion criteria 1. Age from 25 to 70 years.  
2. Refusal of CPAP treatment.  
3. AHI ≥20 events/h.  
4. BMI 25-40 kg/m2.  
5. Modified Mallampati score from I to III23 and  
palatine tonsils assessed as grade 0, 1 or 2 
Age of patients (yrs), Mean (SD) 50.3 (9.6) 
Body mass index (kg/m2), Mean (SD) 30.5 (3.4) 
Sex  13 male, 1 female 
Follow-up (months) 12 
Loss to follow-up, n (%) 1/14 (7) 
Safety-related Outcomes 
Time since implantation 12 months 
Serious Adverse Device Effect (SADE), n (%)  3/13* (23) 
Death 0 
System explants (defective connector at surgery) 1/14 
Broken lead, defective IPG 3/13 
System (device or therapy) or  
procedure-related adverse events, n (%) 
64 events, 14/14* (100) 
* Totals refer to number of patients with an event (i.e., one subject may have had >1 event of a given severity);  
IPG = implanted pulse generator; pts = patients; SD = Standard deviation; yrs = years 
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 Modified Mallampati Scoring: Class I: Soft palate, uvula, fauces, pillars visible. Class II: Soft palate, uvula, fauces 














Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [73] and in the Guidelines of EUnetHTA [22].  
Table A-3: Risk of bias – study level (randomised studies), see [22] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Woodson et al. 2014 Unclear Unclear No No Yes Yes High24 
Smart et al. 201325 n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
n.a. = not applicable  
Table A-4: Risk of bias – study level (case series), see [23] 
IHE QA checklist:  
critical appraisal single-arm studies [23] 















al. 2012 [72] 













1. Is the hypothesis/aim/objective of the study stated clearly in 
the abstract, introduction, or methods section? 
Yes Yes Yes Yes Yes Yes Yes 
Study population 
2. Are the characteristics of the participants included in the 
study described? 
Partial26 Partial26 Yes Partial26 Yes Yes Partial26 
3. Were the cases collected in more than one centre? Yes Yes No Yes Yes Yes Yes 
4. Are the eligibility criteria (inclusion and exclusion criteria) 
for entry into the study explicit and appropriate? 
Yes Yes Yes Yes Yes Yes Yes 
5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
                                                             
24 No details were provided on how randomisation and allocation concealment was achieved 
25
 Insufficient information available to assess the risk of bias (abstract only) 
26























IHE QA checklist:  
critical appraisal single-arm studies [23] 















al. 2012 [72] 












6. Did participants enter the study at similar point in the 
disease?  
Unclear Unclear Yes Unclear27 Yes Yes Unclear 
Intervention and co-intervention 
7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes Yes 
8. Were additional interventions (co-interventions) clearly 
reported in the study? Yes Yes Yes Yes Yes Yes Yes 
Outcome measures 
9. Are the outcome measures clearly defined in the 
introduction or methods section? 
Yes Yes Yes Yes Yes Yes Yes 
10. Were relevant outcomes appropriately measured with 
objective and/or subjective methods? 
Yes Yes Yes Yes Yes Yes Yes 
11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes Yes Yes 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant 
outcomes appropriate? 
Yes Yes Yes Yes Yes Yes Yes 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes Yes Yes Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes Yes Yes Yes Yes Yes 
15. Does the study provide estimates of the random variability 
in the data analysis of relevant outcomes?28 
n/a n/a n/a n/a n/a n/a n/a 
16. Are adverse events reported? Yes Yes Yes Yes Yes Yes Yes 
17. Are the conclusions of the study supported by results? Yes Yes Yes Yes Yes Yes Yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the 
study reported? Yes Yes Yes Yes Yes Yes Yes 
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 Study was conducted in 2 parts. Patients enrolled in part 1 differed in disease severity from patients in part 2. 
28
 This criterion was not applicable for the relevant outcomes that were used for recommendation 
Appendix 
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Applicability table 
Table A-5: Summary table characterising the applicability of a body of studies  
Domain Description of applicability of evidence 
Population All studies included patients with moderate-to-severe obstructive sleep apnea with difficulty 
accepting or adhering to CPAP treatment, respectively with failure of usual treatment options.  
70% of included patients had AHI between 20 and 50 and BMI less than 32. 60% of included 
patients were diagnosed not having complete concentric collapse at the retropalatal airway 
observed in drug-induced sleep endoscopy.  
The inclusion criteria and the population in the studies seem to be in accordance with the intended 
patient population for the technology outlined in the application form. Patient characteristics 
included in studies may not be representative of the population affected by OSA. Both hyplossal 
nerve stimulation systems are approved for treatment of moderate-to-severe obstructive sleep 
apnea in Europe (CE marking).  
Intervention The implantation of hypoglossal nerve stimulation systems was performed using three different 
devices. 157 patients received Inspire® UAS System (Inspire Medical, Inc.) [14, 16-18, 72]. 53 patients 
received HNS/HGNS® (Apnex Medical, Inc.) [15, 19, 20] and 14 patients received Aura6000™ 
System (ImThera Medical, Inc.) [21]. Currently, Inspire® UAS System and Aura6000™ System are 
marketed by two manufacturers, HNS/HGNS® System is not available anymore. 
Surgical implantation of the upper-airway stimulation systems was performed by specialised 
otolaryngologists under general anaesthetics.  
Comparators Both RCTs used “no treatment” as comparator. Although CPAP therapy is the first line therapy in 
moderate-to-severe obstructive sleep apnea, a control group of therapeutic CPAP users is 
impractical because only patients who could not use CPAP, or who declined to do so, are the target 
group of the intervention. 
Outcomes Frequently reported outcomes are AHI (Apnea-hypopnea index), ODI (Oxygen desaturation index), 
ESS (Epworth sleepiness scale) and FOSQ (Functional outcomes of sleep questionnaire). One study 
assessed the short-term RCT withdrawal effect after 1 week, another RCT reported 6 months 
outcomes. Long-term follow-up studies with clinical relevant outcomes like cardiovascular 
morbidity and mortality are lacking. 
Regarding safety outcomes, all case series reported procedure related events, therapy related events 
and device related events. For the assessment of safety, according to the guidelines of medical 
devices on serious adverse event reporting, the reported events were categorized as serious adverse 
event (SAE), adverse event (AE) and serious adverse device effect (SADE). One of the case series 
with 126 participants reported safety outcomes up to 40 months, two case series at 6 months and 
two at 12 months. 
Setting With one exception, the studies were conducted in more than one country. The studies were carried 
out in Germany, Belgium, Israel, the Netherlands, the USA and Australia. A team of experts in sleep 
medicine and otolaryngologists were involved in patient recruitment, the operations were 
performed at otolaryngologic centres inpatiently. Study centres had an experience in sleep related 
disorders and in the technology used, as well as in clinical research in general. The settings of the 
studies reflects the clinical setting in which the technology is intended to be used in an appropriate 


























List of ongoing studies 








completion date Sponsor 
NCT02263859 
Targeted Hypoglossal 
Neurostimulation Study #3  
141 
moderate-to-
severe OSA that 
have failed or do 
not tolerate PAP 
Implantation of 
aura6000 System, 
therapy turned ON 
at the Month 1 
follow-up visit. 
Implantation of aura6000TM System, 
treatment as usual, (i.e. any non-PAP, 
non-surgical OSA treatment including 
oral appliances and positional devices 
being used prior to enrollment in the 
study) until 14 days (washout period) 
prior to the Month 4 visit. Therapy 
turned ON at the Month 4 + 1 day 
Improvement in Apnea 
Hypopnea Index (AHI) 
Improvement  
in Oxygen Desaturation 
Index (ODI) 
Safety Analysis 
May 2016 ImThera 
Medical, Inc. 
Table A-7: List of ongoing single arm studies of HGNS stimulation 




Date Completion Date Number of patients Sponsor 
NCT01796925 Targeted Hypoglossal Neurostimulation 
Study #2 
Completed No Results 
Available 
February 2013 September 2014 57 ImThera Medical, 
Inc. 
NCT02293746 Inspire® Upper Airway Stimulation (UAS) 





June 2014 Estimated  
April 2016 
60 Inspire Medical 
Systems, Inc. 








NCT02413970 Inspire® Post-Approval Study/Protocol 
Number 2014-001 
Recruiting No Results 
Available 
May 2015 December 2021 127 Inspire Medical 
Systems, Inc. 
NCT02312479 Safety and Performance Study of the 
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Literature search strategies 
Search strategy for Medline via OVID 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2015>, Ovid MEDLINE(R) In-Process &  
Other Non-Indexed Citations <December 17, 2015>, Ovid MEDLINE(R) Daily Update <November 18, 2015>,  
Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 exp Sleep Apnea, Obstructive/(13,855) 
2  exp Sleep Apnea Syndromes/(26,835) 
3 sleep apn?ea*.mp. (32,570) 
4 snore*.mp. (1,452) 
5 snoring.mp. (5,966) 
6 1 or 2 or 3 or 4 or 5 (34,626) 
7 exp Cranial Nerves/(101,025) 
8 exp Electric Stimulation/(120,677) 
9 exp Electric Stimulation Therapy/(64,207) 
10 8 or 9 (182,881) 
11 7 and 10 (10,685) 
12 ((cranial or hypoglossal) adj10 stimulation*).mp. (970) 
13 (nerve* adj10 stimulat*).mp. (47,759) 
14 hypoglossal cranial nerve stimulation*.mp. (0) 
15 hypo-glossal cranial nerve stimulation*.mp. (0) 
16 HNS.mp. (1,102) 
17 11 or 12 or 13 or 16 (54,702) 
18 6 and 17 (207) 
19 (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-analy* 
or metaanaly* or “research synthesis“ or ((information or data) adj3 synthesis) or (data adj2 extract*))).ti,ab. 
or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not “psycinfo database“) or 
pubmed or scopus or “sociological abstracts“ or “web of science“).ab. or (“cochrane database of systematic 
reviews“ or evidence report technology assessment or evidence report technology assessment summary).jn. or 
Evidence Report: Technology Assessment*.jn. or ((review adj5 (rationale or evidence)).ti,ab. and review.pt.) or 
meta-analysis as topic/or Meta-Analysis.pt. (260,668) 
20 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/not humans.sh.) (3,224,997) 
21 19 or 20 (338,3575) 
22 18 and 21 (42) 
23 remove duplicates from 22 (36) 
Search date: 18th December 2015 
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Search strategy for Embase 
No. Query Results  Results Date 
#27 ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring AND (‘cranial 
nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp) OR 
(cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* OR nerve* 
NEAR/10 stimulat* OR hns:ab,ti) AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de 
OR ‘cohort analysis’/ de OR ‘controlled study’/de OR ‘major clinical study’/de OR 
‘multicenter study’/de OR ‘multicenter study (topic)’/de OR ‘prospective study’/de 
OR ‘randomized controlled trial’/de OR ‘randomized controlled trial (topic)’/de) 
AND ‘human’/de OR (‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep 
apneas’ OR ‘sleep apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring 
AND (‘cranial nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation 
therapy’/exp) OR (cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* 
OR nerve* NEAR/10 stimulat* OR hns:ab,ti) AND ([cochrane review]/lim OR 
[systematic review]/lim OR [controlled clinical trial]/lim OR [randomized 
controlled trial]/lim OR [meta analysis]/lim)) 
135 18 Dec 2015 
#26. ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring AND (‘cranial 
nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp) OR 
(cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* OR nerve* 
NEAR/10 stimulat* OR hns:ab,ti) AND ([cochrane review]/lim OR [systematic 
review]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim 
OR [meta analysis]/lim) 
21 18 Dec 2015 
#25. ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring AND (‘cranial 
nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp) OR 
(cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* OR nerve* 
NEAR/10 stimulat* OR hns:ab,ti) AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de 
OR ‘cohort analysis’/ de OR ‘controlled study’/de OR ‘major clinical study’/de OR 
‘multicenter study’/de OR ‘multicenter study (topic)’/de OR ‘prospective study’/de 
OR ‘randomized controlled trial’/de OR ‘randomized controlled trial (topic)’/de) 
AND ‘human’/de 
130 18 Dec 2015 
#24. ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring AND (‘cranial 
nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp) OR 
(cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* OR nerve* 
NEAR/10 stimulat* OR hns:ab,ti) AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de 
OR ‘cohort analysis’/ de OR ‘controlled study’/de OR ‘major clinical study’/de OR 
‘multicenter study’/de OR ‘multicenter study (topic)’/de OR ‘prospective study’/de 
OR ‘randomized controlled trial’/de OR ‘randomized controlled trial (topic)’/de) 
169 18 Dec 2015 
#23. ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring AND (‘cranial 
nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp) OR 
(cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* OR nerve* 
NEAR/10 stimulat* OR hns:ab,ti) 
602 18 Dec 2015 
#22. cranial nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation 
therapy’/exp) OR (cranial OR hypoglossal OR ‘hypoglossal’) NEAR/10 stimulation* 
OR nerve* NEAR/10 stimulat* OR hns:ab,ti 
100,154 18 Dec 2015 
#21. hns:ab,ti  1,197 18 Dec 2015 
#20. ‘hypo-glossal cranial nerve stimulations’   18 Dec 2015 
#19. ‘hypoglossal cranial nerve stimulations’  18 Dec 2015 
#18. ‘hypo-glossal cranial nerve stimulation’   18 Dec 2015 
#17. ‘hypoglossal cranial nerve stimulation’   18 Dec 2015 
#16. nerve* NEAR/10 stimulat*  95,730 18 Dec 2015 
#15. (cranial OR hypoglossal OR ‘hypo glossal’) NEAR/10 stimulation* 1,080 18 Dec 2015 
#14. ‘cranial nerve’/exp AND (‘electrostimulation’/exp OR ‘electrostimulation 
therapy’/exp) 
8,189 18 Dec 2015 
#13. ‘electrostimulation’/exp OR ‘electrostimulation therapy’/exp 258,953 18 Dec 2015 
#12. electrostimulation therapy’/exp  195,462 18 Dec 2015 
#11. ‘electrostimulation’/exp  73,409 18 Dec 2015 
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No. Query Results  Results Date 
#10. ‘cranial nerve’/exp  89,666 18 Dec 2015 
#9. ‘sleep disordered breathing’/exp OR ‘sleep apnea’ OR ‘sleep apneas’ OR ‘sleep 
apnoea’ OR ‘sleep apnoeas’ OR ‘snoring’/exp OR snore* OR snoring 
57,541 18 Dec 2015 
#8. snoring  10,234 18 Dec 2015 
#7. snore*  2,121 18 Dec 2015 
#6. ‘snoring’/exp  8,773 18 Dec 2015 
#5. ‘sleep apnoeas’  111 18 Dec 2015 
#4. ‘sleep apnoea’  7,321 18 Dec 2015 
#3. ‘sleep apneas’  487 18 Dec 2015 
#2. ‘sleep apnea’  34,582 18 Dec 2015 
#1. ‘sleep disordered breathing’/exp  51,760 18 Dec 2015 
 
 
Search strategy for CRD (DARE-NHS EED-HTA) 
#### Electric nerve stimulation for Sleep Apnea  
1 MeSH DESCRIPTOR Sleep Apnea, Obstructive EXPLODE ALL TREES 
2 MeSH DESCRIPTOR Sleep Apnea Syndromes EXPLODE ALL TREES 
3 (sleep apn*ea*) 
4 MeSH DESCRIPTOR Snoring EXPLODE ALL TREES 
5 (snore*) 
6 (snoring) 
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 
8 MeSH DESCRIPTOR Electric Stimulation EXPLODE ALL TREES 
9 MeSH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES 
10 (stimulat*) 
11 MeSH DESCRIPTOR Hypoglossal Nerve EXPLODE ALL TREES 
12  MeSH DESCRIPTOR Cranial Nerves EXPLODE ALL TREES 
13 ((cranial OR hypoglossal) NEAR stimulat*) 
14 ((cranial OR hypo-glossal) NEAR stimulat*) 
15  #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 
16 #7 AND #15 
7 Hits 




Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea 
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Search strategy for Cochrane Library 
Search Name: HNS for Sleep Apnea 
Last Saved: 21.12.2015 17:41:58  
ID Search 
#1 MeSH descriptor: [Sleep Apnea, Obstructive] explode all trees 
#2 MeSH descriptor: [Sleep Apnea Syndromes] explode all trees 
#3 MeSH descriptor: [Snoring] explode all trees 
#4 sleep apnea* (Word variations have been searched) 
#5 sleep apnoea* (Word variations have been searched) 
#6 snore* (Word variations have been searched) 
#7 snoring (Word variations have been searched) 
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7  
#9 MeSH descriptor: [Cranial Nerves] explode all trees 
#10 MeSH descriptor: [Electric Stimulation] explode all trees 
#11 MeSH descriptor: [Electric Stimulation Therapy] explode all trees 
#12 #10 or #11  
#13 #9 and #12  
#14 (cranial or hypoglossal) near stimulation* (Word variations have been searched) 
#15 nerve* near stimulat* (Word variations have been searched) 
#16 hypoglossal cranial nerve stimulation* (Word variations have been searched) 
#17 hypo-glossal cranial nerve stimulation* (Word variations have been searched) 
#18 HNS:ti,ab,kw (Word variations have been searched) 
#19 #13 or #14 or #15 or #16 or #18  




Search strategy for PubMed 
PubMed Suchstring: 
(((((Sleep Apnea, Obstructive[Mesh] OR Sleep Apnea Syndromes[Mesh] OR sleep apnea* OR sleep apnoea* OR 
snore* OR snoring[Mesh] OR snoring))) AND ((Cranial Nerves[Mesh] AND (Electric Stimulation[Mesh] OR Electric 
Stimulation Therapy[Mesh]) OR cranial stimulation* OR hypoglossal stimulation* OR nerve* AND stimulat* OR 
hypoglossal cranial nerve stimulation* OR hypo-glossal cranial nerve stimulation* OR HNS[tiab])) AND Clinical 
Trial[ptyp])) OR ((((Sleep Apnea, Obstructive[Mesh] OR Sleep Apnea Syndromes[Mesh] OR sleep apnea* OR sleep 
apnoea* OR snore* OR snoring[Mesh] OR snoring))) AND ((Cranial Nerves[Mesh] AND (Electric Stimulation[Mesh] 
OR Electric Stimulation Therapy[Mesh]) OR cranial stimulation* OR hypoglossal stimulation* OR nerve* AND 
stimulat* OR hypoglossal cranial nerve stimulation* OR hypo-glossal cranial nerve stimulation* OR HNS[tiab])) AND 
((Meta-Analysis[ptyp] OR systematic[sb]))) 
21 Hits 
Search date: 21st December 2015 
 
